Microbial compositions and methods of use for benefiting plant growth and treating plant disease

ABSTRACT

Compositions and methods are provided for a combination of a new strain of  Bacillus amyloliquefaciens  RTI301 and a new strain of  Bacillus subtilis  RTI477, the combination having growth promoting activity and activity against plant pathogens. The compositions containing the RTI301 and RTI477 strains are useful for benefiting plant growth and/or conferring protection against a pathogenic infection when applied to plant roots, seeds, callus tissue, grafts, and cuttings. Synergistic results are observed for the combination of the strains, and the combination of strains is useful to increase yield in crops including soybean and corn. The compositions containing the combination of strains can be applied alone or in combination with other microbial, biological, or chemical insecticides, fungicides, nematicides, bacteriocides, herbicides, plant extracts, plant growth regulators, and fertilizers.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. provisional application No. 62/097,287 filed Dec. 29, 2014, the disclosure of which is hereby incorporated herein by reference in its entirety.

TECHNICAL FIELD

The presently disclosed subject matter relates to compositions comprising isolated microbial strains for application to plants, plant seeds, and the soil surrounding plants to benefit plant growth and to treat plant disease. In certain cases the microbial strains are delivered to the plants, plant seeds, and the soil surrounding plants in combination with a chemical active agent having antimicrobial properties.

BACKGROUND

A number of microorganisms having beneficial effects on plant growth and health are known to be present in the soil, to live in association with plants specifically in the root zone (Plant Growth Promoting Rhizobacteria “PGPR”), or to reside as endophytes within the plant. Their beneficial plant growth promoting properties include nitrogen fixation, iron chelation, phosphate solubilization, inhibition of non-beneficial microorganisms, resistance to pests, Induced Systemic Resistance (ISR), Systemic Acquired Resistance (SAR), decomposition of plant material in soil to increase useful soil organic matter, and synthesis of phytohormones such as indole-acetic acid (IAA), acetoin and 2,3-butanediol that stimulate plant growth, development and responses to environmental stresses such as drought. In addition, these microorganisms can interfere with a plant's ethylene stress response by breaking down the precursor molecule, 1-aminocyclopropane-1-carboxylate (ACC), thereby stimulating plant growth and slowing fruit ripening. These beneficial microorganisms can improve soil quality, plant growth, yield, and quality of crops. Various microorganisms exhibit biological activity such as to be useful to control plant diseases. Such biopesticides (living organisms and the compounds naturally produced by these organisms) are safer and more biodegradable than synthetic fertilizers and pesticides.

Fungal phytopathogens, including but not limited to Botrytis spp. (e.g. Botrytis cinerea), Fusarium spp. (e.g. F. oxysporum and F. graminearum), Rhizoctonia spp. (e.g. R. solani), Magnaporthe spp., Mycosphaerella spp., Puccinia spp. (e.g. P. recondita), Phytopthora spp. and Phakopsora spp. (e.g. P. pachyrhizi), are one type of plant pest that can cause severe economic losses in the agricultural and horticultural industries. Chemical agents can be used to control fungal phytopathogens, but the use of chemical agents suffers from disadvantages including high cost, lack of efficacy, emergence of resistant strains of the fungi, and undesirable environmental impacts. In addition, such chemical treatments tend to be indiscriminant and may adversely affect beneficial bacteria, fungi, and arthropods in addition to the plant pathogen at which the treatments are targeted. A second type of plant pest are bacterial pathogens, including but not limited to Erwinia spp. (such as Erwinia chrysanthemi), Pantoea spp. (such as P. citrea), Xanthomonas (e.g. Xanthomonas campestris), Pseudomonas spp. (such as P. syringae) and Ralstonia spp. (such as R. soleacearum) that cause severe economic losses in the agricultural and horticultural industries. Similar to pathogenic fungi, the use of chemical agents to treat these bacterial pathogens suffers from disadvantages. Viruses and virus-like organisms comprise a third type of plant disease-causing agent that is hard to control, but to which bacterial microorganisms can provide resistance in plants via induced systemic resistance (ISR). Thus, microorganisms that can be applied as biofertilizer and/or biopesticide to control pathogenic fungi, viruses, and bacteria are desirable and in high demand to improve agricultural sustainability. A final type of plant pathogen includes plant pathogenic nematodes and insects, which can cause severe damage and loss of plants.

Some members of the species Bacillus have been reported as biocontrol strains, and some have been applied in commercial products (Joseph W. Kloepper, et al. 2004, Phytopathology Vol. 94, No. 11, 1259-1266). For example, strains currently being used in commercial biocontrol products include: Bacillus pumilus strain QST2808, used as active ingredient in SONATA and BALLAD-PLUS, produced by BAYER CROP SCIENCE; Bacillus pumilus strain GB34, used as active ingredient in YIELDSHIELD, produced by BAYER CROP SCIENCE; Bacillus subtilis strain QST713, used as the active ingredient of SERENADE, produced by BAYER CROP SCIENCE; Bacillus subtilis strain GBO3, used as the active ingredient in KODIAK and SYSTEM3, produced by HELENA CHEMICAL COMPANY. Various strains of Bacillus thuringiensis and Bacillus firmus have been applied as biocontrol agents against nematodes and vector insects and these strains serve as the basis of numerous commercially available biocontrol products, including NORTICA and PONCHO-VOTIVO, produced by BAYER CROP SCIENCE. In addition, Bacillus strains currently being used in commercial biostimulant products include: Bacillus amyloliquefaciens strain FZB42 used as the active ingredient in RHIZOVITAL 42, produced by ABiTEP GmbH, as well as various other Bacillus subtilus species that are included as whole cells including their fermentation extract in biostimulant products, such as FULZYME produced by JHBiotech Inc.

The presently disclosed subject matter provides microbial compositions and methods for their use in benefiting plant growth and treating plant disease.

SUMMARY OF THE INVENTION

In one embodiment a composition is provided for benefiting plant growth and/or plant health, the composition comprising: a biologically pure culture of Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof; and a biologically pure culture of Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof, wherein application of the composition to seed of the plant, roots of the plant, or soil surrounding the plant benefits plant growth and/or plant health.

In one embodiment a method is provided for benefiting plant growth and/or plant health, the method comprising delivering to seed of a plant, roots of a plant, or soil surrounding a plant a composition comprising: a biologically pure culture of a Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof; and a biologically pure culture of a Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof, wherein delivery of the composition benefits the plant growth and/or plant health.

In one embodiment a method is provided for benefiting plant growth and/or plant health, the method comprising: delivering to seed of a plant, roots of a plant, or soil surrounding a plant a combination of: a first composition comprising a biologically pure culture of a Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof; and a second composition comprising a biologically pure culture of a Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof, wherein delivery of the combination benefits the plant growth and/or plant health.

In one embodiment a plant seed is provided, wherein the plant seed is coated with a composition for benefiting plant growth and/or plant health, the composition comprising: spores of a biologically pure culture of Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof; and spores of a biologically pure culture of Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof.

In one embodiment, a plant seed is provided, wherein the plant seed is coated with a composition for benefiting plant growth and/or plant health, the composition comprising: spores of a biologically pure culture of Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof; spores of a biologically pure culture of Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof; and a bifenthrin insecticide.

In one embodiment a method is provided for benefiting plant growth and/or plant health, the method comprising planting a seed of a plant in a suitable growth medium, wherein the seed has been coated with a composition comprising: spores of a biologically pure culture of Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof; and spores of a biologically pure culture of Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof, present in an amount suitable to benefit the plant growth and/or plant health.

In one embodiment a composition is provided for benefiting plant growth, the composition comprising: a biologically pure culture of Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof; a biologically pure culture of Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof; and a bifenthrin insecticide.

In one embodiment a composition is provided for benefiting plant growth, the composition comprising: a biologically pure culture of Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof; a biologically pure culture of Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof; and a bifenthrin insecticide, wherein the composition is in a formulation compatible with a liquid fertilizer.

In one embodiment, a composition is provided for benefiting plant growth, the composition comprising: a biologically pure culture of Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof; a biologically pure culture of Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof; and a fungicide comprising one or a combination of an extract from Lupinus albus doce, a BLAD polypeptide, or a fragment of a BLAD polypeptide.

In one embodiment, a product is provided, the product comprising: a first composition comprising a biologically pure culture of Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof and a biologically pure culture of Bacillus amyloliquefaciens RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof; a second composition comprising one or a combination of a microbial, a biological, or a chemical insecticide, fungicide, nematicide, bacteriocide, herbicide, plant extract, plant growth regulator, or fertilizer, wherein the first and second composition are separately packaged; and, optionally, instructions for delivering in an amount suitable to benefit plant growth, a combination of the first and second compositions to: foliage of the plant, bark of the plant, fruit of the plant, flowers of the plant, seed of the plant, roots of the plant, a cutting of the plant, a graft of the plant, callus tissue of the plant; soil or growth medium surrounding the plant; soil or growth medium before sowing seed of the plant in the soil or growth medium; or soil or growth medium before planting the plant, the plant cutting, the plant graft, or the plant callus tissue in the soil or growth medium.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows a schematic diagram of the genomic organization surrounding and including the unique lantibiotic biosynthesis operon found in Bacillus amyloliquefaciens strain RTI301 as compared to the corresponding regions for two Bacillus amyloliquefaciens reference strains, Bacillus amyloliquefaciens FZB42 and Bacillus amyloliquefaciens TrigoCor1448 according to one or more embodiments of the present invention.

FIG. 2A is an image of extracted wheat plants after 13 days growth showing control plants. FIG. 2B is an image of extracted wheat plants after 13 days growth showing plants inoculated with the RTI477 strain. These images show the positive effects of Bacillus subtilis strain RTI477 on early plant growth in wheat according to one or more embodiments of the present invention.

FIG. 3A is an image showing the strain Bacillus amyloliquefaciens RTI301 spotted onto a lawn of strain Bacillus amyloliquefaciens RTI472. FIG. 3B is an image showing the strain Bacillus amyloliquefaciens RTI301 spotted onto a lawn of strain Bacillus subtilis RTI477. These images show the compatibility between Bacillus amyloliquefaciens strain RTI301 and Bacillus subtilis strain RTI477 according to one or more embodiments of the present invention.

FIG. 4A is an image showing the morphology of strain Bacillus amyloliquefaciens RTI301 according to one or more embodiments of the present invention. FIG. 4B is an image showing the morphology of strain Bacillus subtilis RTI477 according to one or more embodiments of the present invention.

FIG. 5A shows control plants. FIG. 5B shows plants inoculated with RTI301 plus RTI477 (ratio 3:1) at 10⁶ cfu/ml. FIGS. 5A-5B are images showing the positive effect on early plant growth resulting from inoculation of soybean seed with the combination of Bacillus amyloliquefaciens RTI301 plus Bacillus subtilis strain RTI477 and extracted after 8 days growth according to one or more embodiments of the present invention.

FIG. 6 is a schematic diagram showing both previously reported Fengycin-type and Dehydroxyfengycin-type cyclic lipopeptides produced by microbial species including Bacillus amyloliquefaciens and Bacillus subtilis and newly identified (shown in bold type) Fengycin- and Dehydroxyfengycin-type molecules produced by one or both of the Bacillus amyloliquefaciens RTI301 and Bacillus subtilus RTI477 isolates according to one or more embodiments of the present invention.

DETAILED DESCRIPTION

The terms “a,” “an,” and “the” refer to “one or more” when used in this application, including the claims. Thus, for example, reference to “a plant” includes a plurality of plants, unless the context clearly is to the contrary.

Throughout this specification and the claims, the terms “comprise,” “comprises,” and “comprising” are used in a non-exclusive sense, except where the context requires otherwise. Likewise, the term “include” and its grammatical variants are intended to be non-limiting, such that recitation of items in a list is not to the exclusion of other like items that can be substituted or added to the listed items.

For the purposes of this specification and claims, the term “about” when used in connection with one or more numbers or numerical ranges, should be understood to refer to all such numbers, including all numbers in a range and modifies that range by extending the boundaries above and below the numerical values set forth. The recitation of numerical ranges by endpoints includes all numbers, e.g., whole integers, including fractions thereof, subsumed within that range (for example, the recitation of 1 to 5 includes 1, 2, 3, 4, and 5, as well as fractions thereof, e.g., 1.5, 2.25, 3.75, 4.1, and the like) and any range within that range.

For the purposes of this specification and claims, the terms “metabolite” and “compound” are used interchangeably when used in connection with compounds having antimicrobial activity that are produced by the RTI301 strain or other Bacillus amyloliquefaciens strains.

In one or more embodiments of the present invention, compositions and methods are provided for benefiting plant growth and/or plant health. In one embodiment, a composition is provided for benefiting plant growth and/or plant health, the composition including two or more compatible microorganisms, where a first microorganism with antimicrobial properties is used to create a niche by inhibiting the growth and development of endogenous microorganisms present in the soil or living in association with the plant. The second microorganism has properties beneficial to plant growth and/or plant health and is compatible with growth of the first microorganism. The second microorganism is present in an amount sufficient to become established and to benefit the plant growth and/or plant health. Application of the composition to seed of the plant, roots of the plant, or soil surrounding the plant benefits plant growth and/or plant health. The properties of the second microorganism that are beneficial to plant growth and/or plant health include one of increased plant yield, improved seedling vigor, improved root development, improved plant growth, improved plant health, improved appearance, improved resistance to plant pathogens, reduced pathogenic infection, or a combination thereof. The plant pathogen can include one or a combination of insects, nematodes, plant pathogenic fungi, or plant pathogenic bacteria.

In another embodiment, a method is provided for benefiting plant growth and/or plant health, the method comprising delivering to seed of a plant, roots of a plant, or soil surrounding a plant, a composition that includes two or more compatible microorganisms. The composition includes at least one biologically pure culture of a first microorganism having antimicrobial properties and present in an amount suitable for inhibiting growth of endogenous microorganisms present in soil surrounding or living in association with the plant. This is to establish a niche for a second microorganism to become established. The composition also includes at least one biologically pure culture of a second microorganism having properties beneficial to plant growth and/or plant health, wherein growth of the second microorganism is compatible with growth of the first microorganism, and wherein the second microorganism is present in an amount suitable to become established and to benefit the plant growth and/or plant health. Delivery of the composition to seed of the plant, roots of the plant, or soil surrounding the plant benefits the plant growth and/or plant health.

To facilitate the process of establishment of the second microorganism, the growth of the second microorganism can be faster than that of the first microorganism and the second microorganism can be characterized by a swarming and high motility phenotype.

The compositions and methods include use with any type of plant including, for example, monocots, dicots, Cereals, Corn, Sweet Corn, Popcorn, Seed Corn, Silage Corn, Field Corn, Rice, Wheat, Barley, Sorghum, Asparagus, Berry, Blueberry, Blackberry, Raspberry, Loganberry, Huckleberry, Cranberry, Gooseberry, Elderberry, Currant, Caneberry, Bushberry, Brassica Vegetables, Broccoli, Cabbage, Cauliflower, Brussels Sprouts, Collards, Kale, Mustard Greens, Kohlrabi, Cucurbit Vegetables, Cucumber, Cantaloupe, Melon, Muskmelon, Squash, Watermelon, Pumpkin, Eggplant, Bulb Vegetables, Onion, Garlic, Shallots, Citrus, Orange, Grapefruit, Lemon, Tangerine, Tangelo, Pummelo, Fruiting Vegetables, Pepper, Tomato, Ground Cherry, Tomatillo, Okra, Grape, Herbs/Spices, Leafy Vegetables, Lettuce, Celery, Spinach, Parsley, Radicchio, Legumes/Vegetables (succulent and dried beans and peas), Beans, Green beans, Snap beans, Shell beans, Soybeans, Dry Beans, Garbanzo beans, Lima beans, Peas, Chick peas, Split peas, Lentils, Oil Seed Crops, Canola, Castor, Coconut, Cotton, Flax, Oil Palm, Olive, Peanut, Rapeseed, Safflower, Sesame, Sunflower, Soybean, Pome Fruit, Apple, Crabapple, Pear, Quince, Mayhaw, Root/Tuber and Corm Vegetables, Carrot, Potato, Sweet Potato, Cassave, Beets, Ginger, Horseradish, Radish, Ginseng, Turnip, Stone Fruit, Apricot, Cherry, Nectarine, Peach, Plum, Prune, Strawberry, Tree Nuts, Almond, Pistachio, Pecan, Walnut, Filberts, Chestnut, Cashew, Beechnut, Butternut, Macadamia, Kiwi, Banana, (Blue) Agave, Grass, Turf grass, Ornamental plants, Poinsettia, Hardwood cuttings, Chestnuts, Oak, Maple, sugarcane, or sugarbeet.

The first microorganism having antimicrobial properties and the second microorganism having properties beneficial to plant growth and/or plant health for use in the compositions and methods of the present invention can be Bacillus spp. microorganisms. The terms “antagonistic” and “antimicrobial” are used interchangeably herein for the purposes of the specification and claims. The first microorganism can be a Bacillus spp. strain and the Bacillus spp. strain can be a Bacillus amyloliquefaciens. The second microorganism having properties beneficial to plant growth and/or plant health can be a Bacillus subtilis. The properties beneficial to plant growth and/or plant health can be one or both of growth promoting properties and antagonistic properties to confer protection against plant pathogenic infections and/or to treat or control plant pathogenic infections.

Examples of the first microorganism having antimicrobial properties and the second microorganism having properties beneficial to plant growth and/or plant health for use in the compositions and methods of the present invention are described below. For example, a plant-associated bacterium, identified as belonging to the species Bacillus subtilis, was isolated from the root of Moringa oleifera grown in North Carolina and subsequently tested for plant growth promoting and plant pathogen antagonistic properties. More specifically, the isolated bacterial strain was identified as being a new strain of Bacillus subtilis through sequence analysis of highly conserved 16S rRNA and rpoB genes (see EXAMPLE 1). The 16S RNA sequence of the new bacterial isolate (designated “Bacillus subtilis RTI477”) was determined to be identical to the 16S rRNA gene sequence of three other known strains of Bacillus subtilis, Bacillus amyloliquefaciens strain NS6 (KF177175), and Bacillus subtilis subsp. subtilis strain DSM 10 (NR_027552). In addition, it was determined that the rpoB sequence of RTI477 has the highest level of sequence similarity to the known Bacillus subtilis PY79 (CP006881) or Bacillus subtilis subsp. subtilis 6051-HGW (CP003329) strains (i.e., 99% sequence identity; 9 bp difference) or Bacillus subtilis subsp. subtilis BAB-1a (CP004405) (i.e., 99% sequence identity; 10 bp difference). The differences in sequence for the rpoB gene at the DNA level indicate that RTI477 is a new strain of Bacillus subtilis. The strain of Bacillus subtilis RTI477 was deposited on 17 Apr. 2014 under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure at the American Type Culture Collection (ATCC) in Manassas, Va., USA and bears the Patent Accession No. PTA-121167.

As an example of the first microorganism having antimicrobial properties, a plant-associated bacterium, identified as belonging to the species Bacillus amyloliquefaciens, was isolated from the rhizosphere soil of grape vines growing at a vineyard in NY and subsequently tested for plant pathogen antagonistic properties. More specifically, the isolated bacterial strain was identified as being a new strain of Bacillus amyloliquefaciens through sequence analysis of highly conserved 16S rRNA and rpoB genes (see EXAMPLE 2). The 16S RNA sequence of the new bacterial isolate (designated “Bacillus amyloliquefaciens RTI301”) was determined to be identical to the 16S rRNA gene sequence of three other known strains of Bacillus amyloliquefaciens, Bacillus amyloliquefaciens strain NS6 (KF177175), Bacillus amyloliquefaciens strain FZB42 (NR_075005), and Bacillus subtilis subsp. subtilis strain DSM 10 (NR_027552). It was also determined that the rpoB gene sequence of the RTI301 strain has sequence similarity to the same gene in Bacillus amyloliquefaciens subsp. plantarum TrigoCor1448 (CP007244) (99% sequence identity; 3 base pair difference); Bacillus amyloliquefaciens subsp. plantarum AS43.3 (CP003838) (99% sequence identity; 7 base pair difference); Bacillus amyloliquefaciens CC178 (CP006845) (99% sequence identity; 8 base pair difference), and Bacillus amyloliquefaciens FZB42 (CP000560) (99% sequence identity; 8 base pair difference). The RTI301 strain was identified as a Bacillus amyloliquefaciens. The differences in sequence for the rpoB gene at the DNA level indicate that RTI301 is a new strain of Bacillus amyloliquefaciens. The strain of Bacillus amyloliquefaciens RTI301 was deposited on 17 Apr. 2014 under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure at the American Type Culture Collection (ATCC) in Manassas, Va., USA and bears the Patent Accession No. PTA-121165.

Further sequence analysis of the genome of the Bacillus amyloliquefaciens RTI301 strain revealed that the strain has genes related to lantibiotic biosynthesis for which homologues are lacking in the other closely related Bacillus amyloliquefaciens RTI301 strains (see EXAMPLE 3). This is illustrated in FIG. 1 which shows a schematic diagram of the genomic organization of the unique lantibiotic biosynthetic cluster found in Bacillus amyloliquefaciens RTI301 and the corresponding region for two known Bacillus amyloliquefaciens reference strains, FZB42 (middle) and TrigoCor1448 (bottom), shown below the RTI301 strain. It can be observed from FIG. 1 that FZB42 and TrigoCor1448 strains lack many of the genes present in this cluster, and there is a low degree of sequence identity within a number of the genes that are present. BLASTn analysis of this cluster against the non-redundant (nr) nucleotide database at NCBI showed high homology to the 5′ and 3′ flanking regions (analogous to the high % similarity in FIG. 1) to B. amyloliquefaciens strains. However, the lantipeptide biosynthetic cluster was unique to RTI301, and no significant homology to any previously sequenced DNA in the NCBI nr database was observed. The data indicate that the newly identified RTI301 has a unique lantibiotic biosynthesis pathway.

In addition, further sequence analysis of the genome of the Bacillus amyloliquefaciens RTI301 strain revealed that this strain has genes related to a large number of biosynthetic pathways for production of molecules having antimicrobial properties. These include the biosynthetic pathways for subtilosin, surfactin, iturin, fengycins, amylocyclicin, difficidin, bacilysin, bacillomycin, and bacillaene. In contrast to the RTI301 strain with its wide range of antimicrobial biosynthetic pathways, further sequence analysis of the RTI477 strain revealed that this strain has genes related to biosynthetic pathways for a more limited group of molecules having antimicrobial properties. The RTI477 strain has biosynthetic pathways for subtilosin, fengycins, surfactin, difficidin, bacillaene, bacilysin, and bacillomycin, but complete biosynthetic pathways for iturins, lantibiotics, and amylocyclicins were not observed.

Experiments were performed to determine the growth promoting and antagonistic activities of the RTI301 and RTI477 strains. Experiments performed to determine the growth promoting and antagonistic activities of the Bacillus subtilis RTI477 strain in various plants and under varying conditions are described herein at EXAMPLEs 4-6. EXAMPLE 4 describes the antagonistic activity of the Bacillus subtilis RTI477 isolate against major plant pathogens as measured in plate assays. EXAMPLE 5 describes measurement of various phenotypic traits of the Bacillus subtilis RTI477 isolate and shows that this isolate has a fast growing and strong swarming phenotype. EXAMPLE 6 describes the growth promoting activity of the RTI477 isolate in wheat. Germinated wheat seeds were inoculated for 2 days in a suspension of ^(˜)2×10⁷ CFU/ml of the RTI477 strain and subsequently planted in pots. Photographs of the extracted plants after 13 days growth are shown in FIG. 2. FIG. 2A shows control plants and FIG. 2B shows plants inoculated with RTI477. Dry weight of the wheat seedlings was determined resulting in a total average dry plant weight equal to 35.41 mg for the plants inoculated with the Bacillus subtilis RTI477 strain versus a weight equal to 33.38 mg for the non-inoculated control which is a 6% increase in dry weight over the non-inoculated control for the RTI477 treated plants.

Similar to the RTI477 strain, experiments were performed to determine the growth promoting and antagonistic activities of the amyloliquefaciens RTI301 strain in various plants and under varying conditions. These experiments are described herein at EXAMPLEs 4-5. EXAMPLE 4 describes the antagonistic activity of the amyloliquefaciens RTI301 isolate against major plant pathogens as measured in plate assays. The RTI301 strain showed superior antagonistic properties against a wide range of plant pathogenic microorganisms in comparison to the RTI477 strain. EXAMPLE 5 describes measurement of various phenotypic traits of the amyloliquefaciens RTI301 isolate. Notably, as compared to RTI301, RTI477 grows faster and has a strong swarming phenotype.

The compatibility of the strain Bacillus amyloliquefaciens RTI301 with other Bacillus isolates was tested by spotting the RTI301 strain onto a lawn of the various other strains. These data are described in EXAMPLE 7. Results of this experiment are shown in FIGS. 3A-3B. FIGS. 3A-3B are images showing the growth compatibility between strains Bacillus amyloliquefaciens RTI301 and Bacillus subtilis RTI477 and a lack of compatibility between the RTI301 strain with another Bacillus amyloliquefaciens strain, Bacillus amyloliquefaciens RTI472 deposited as PTA-121166 with the American Type Culture Collection (ATCC). When strain RTI301 was spotted onto a lawn of strain RTI472 (FIG. 3A), a clear inhibition zone was observed for the growth of strain RTI472. In contrast, when strain RTI301 was spotted onto a lawn of strain RTI477 (FIG. 3B), only minimal inhibition and no clearing of the cell lawn was observed for the RTI477 strain. Therefore, it was concluded that the growth of RTI301 and RTI477 is compatible.

Without being limited to any particular mechanism of action, one mode of action is proposed as follows to explain the observed differences in strain compatibility. Based on the genome sequences of the three strains tested (i.e., RTI301, RTI472, and RTI477), these strains were all predicted to produce the antagonistic compounds bacilysin, bacillaene, difficidin, and bacillomycin. However, while both Bacillus amyloliquefaciens RTI301 and Bacillus subtilis RTI477 possess the gene for synthesis of subtilosin, this gene is absent in the genome of Bacillus amyloliquefaciens RTI472. Subtilosin is a bacteriocin, a class of proteinaceous toxins produced by bacteria to inhibit the growth of similar or closely related bacterial strain(s). Therefore, it was postulated that the subtilosin synthesized by Bacillus amyloliquefaciens RTI301 could be the inhibitor of the growth of Bacillus amyloliquefaciens RTI472. In contrast, the Bacillus subtilis RTI477 strain is not inhibited by RTI301, because the RTI477 strain produces its own subtilosin and is thus resistant to the compound.

The differences in strain morphology between the Bacillus amyloliquefaciens RTI301 and Bacillus subtilis RTI477 strains were also analyzed. Images showing the morphology of each of these strains are shown in FIG. 4: Bacillus amyloliquefaciens RTI301 (FIG. 4A) and Bacillus subtilis RTI477 (FIG. 4B). The colony morphology of the Bacillus amyloliquefaciens RTI301 and Bacillus subtilis RTI477 strains shown in FIGS. 4A-4B indicate a potential difference in strain behavior when it comes to motility. Motility is a key trait for rhizosphere colonization by plant associated bacteria. Bacillus amyloliquefaciens RTI301 grows as well-defined, round colonies. In contrast, Bacillus subtilis RTI477 grows as a fluffy colony, a morphology which is indicative of swarming and motility. Swarming and motility are relevant phenotypes for the rapid colonization of the rhizosphere and the surface of the plant root. Again, without being limited to any particular mechanism of action, it was postulated that the strong swarming phenotype associated with the morphology of the Bacillus subtilis RTI477 strain, causes this strain to be a more efficient colonizer of the rhizosphere than Bacillus amyloliquefaciens RTI301.

In light of the growth compatibility and observed differences in phenotype, the combination of the RTI301 and RTI477 strains was tested for its ability to promote plant growth and health. Experiments were performed to determine the effects of application of the Bacillus subtilis RTI477 and Bacillus amyloliquefaciens RTI301 strains, alone and in combination, to soybean seed on germination, root development, and early plant growth. Experiments were performed as described in EXAMPLE 8 using spores of RTI301 and RTI477. Combinations of the RTI301 and RTI477 spores were added to the seeds in ratios of 1:3, 1:1 and 3:1. The data are shown in Table V. Inoculation of soybean seeds with Bacillus amyloliquefaciens RTI301 at concentrations of 1×10⁶, 1×10⁷, and 1×10⁸ had no effect on plant growth, and root development and architecture. Inoculation of soybean seeds with Bacillus subtilis RTI477 at the same concentrations provided only a slight improvement at the lowest concentration on root development and architecture. However, inoculation of soybean seeds with the combination of both RTI301 and RTI477 (at a ratio of 1:3) resulted at all concentrations tested in an improvement in root development and early plant growth. The best results on root development were observed when RTI301 and RTI477 were applied in a ratio of 3:1 at the concentration of 1×10⁶ CFU/ml. Images of the positive effects of inoculation of the seed with the RTI301 plus RTI477 spores at this ratio of 3:1 are shown in FIGS. 5A and 5B (A—Control plants; B—plants inoculated with RTI301 plus RTI477 (ratio 3:1) at 10⁶ cfu/ml). The effects were especially positive with regards to root formation and architecture, as shown in FIGS. 5A-5B. Fine root hairs are important in the uptake of water, nutrients and plant interaction with other microorganisms in the rhizosphere. These results show that while the application of individual strains had no or little effect compared to control plants, seed treatment with application of a combination of Bacillus subtilis RTI477 and Bacillus amyloliquefaciens RTI301 strains provided a greater than expected benefit to soybean early growth and establishment. Synergistic effects of the combination of the Bacillus subtilis RTI477 and Bacillus amyloliquefaciens RTI301 strains were observed and provided unexpected benefits to plant growth.

An additional experiment in soybean was performed to examine the effect of seed treatment with the combination of the RTI301 and RTI477 strains on yield. The experiment was set up as follows: 1) seed was untreated; 2) seed was treated with a combination of CRUISERMAXX (thiamethoxam, fludioxonil plus metalaxyl-M; SYNGENTA CROP PROTECTION, INC) and thiophanate methyl, which is a typical soybean seed treatment (the combination of CRUISERMAXX and thiophanate methyl is referred to as “CHEM CONTROL”); 3) seed was treated with CHEM CONTROL plus inoculated with 5.0×10⁺⁵ cfu/seed of strain RTI301; 4) seed was treated with CHEM CONTROL plus inoculated with 5.0×10⁺⁵ cfu/seed of strain RTI477; 5) seed was treated with CHEM CONTROL plus inoculated with a combination of both strains at 5.0×10⁺⁵ cfu/seed. Ten trials were performed as 10 independent plots and the soybean yield results (bushels per acre) are presented in Table VI. The results in Table VI show that inoculation with either Bacillus amyloliquefaciens RTI301 or Bacillus subtilis RTI477 alone had no effect on the overall yield of soybean when compared to seeds that were treated with the CHEM CONTROL alone. As was observed in the previous experiment, inoculating with the combination of the Bacillus amyloliquefaciens RTI301 and Bacillus subtilis RTI477 provided a synergistic effect and resulted in a 5% increase in soybean yield (from 58.2 to 61.1 bushels per acre). The combination of the Bacillus subtilis RTI477 and Bacillus amyloliquefaciens RTI301 strains provided unexpected benefits to soybean yield.

EXAMPLE 9 describes the benefits of seed treatment with a combination of the Bacillus subtilis RTI477 and Bacillus amyloliquefaciens RTI301 strains in corn. For the corn experiment, the data are summarized in Table VII and the set-up was as follows: 1) seed was untreated (“UTC”); 2) seed was treated with a combination of 3 commonly used chemical active agents referred to as “CHEM CONTROL” or “CC”); and 3) seed was treated with CHEM CONTROL plus a combination of 5.0×10⁺⁵ cfu/seed of each of strains RTI301 and RTI477 (“CC+RTI 301/477 1:1”). Two trials were performed under conditions of natural disease pressure or inoculation of the soil with Rhizoctonia. Notably, a yield increase of 10.7 bushels per acre and 59.8 bushels per acre was observed for the 1:1 combination of RTI301 and RTI477 plus chemical control over the chemical control alone for the natural pathogen pressure and the Rhizoctonia inoculated field trials, respectively. These data indicate that treatment of seed with the combination of these strains can result in very large enhancements in corn yield.

EXAMPLE 10 describes experiments showing the effect on emergence and yield in soybean when seeds are treated with a combination of the RTI301 and RTI477 strains in addition to chemical active agents for pathogen control. Specifically, an experiment in soybean was set up as follows: 1) seed was untreated (UTC); 2) seed was treated with a combination of 3 commonly used chemical active agents referred to as “CHEM CONTROL”); 3) seed was treated with VIBRANCE (active ingredient Sedaxane; SYNGENTA CROP PROTECTION, INC; and 4) seed was treated with CHEM CONTROL plus 5.0×10⁺⁵ cfu/seed of each of strain RTI301 and RTI477. Two trials were performed in which the plant seeds were inoculated with Rhizoctonia solani at planting. The results in Table VIII show that treating with the combination of the Bacillus amyloliquefaciens RTI301 and Bacillus subtilis RTI477 in addition to the CHEM CONTROL resulted in an average increase in yield of 13.3 bushels per acre over that of the CHEM CONTROL alone (from 59.4 to 72.7 bushels per acre). Thus, seed treatment with the combination of RTI301 and RTI477 provides significant improvement in yields in soybean, even under conditions of severe pathogen pressure.

EXAMPLE 11 describes the benefits of drip irrigation with a combination of the Bacillus subtilis RTI477 and the Bacillus amyloliquefaciens RTI301 strains on squash, tomato and pepper. Disease pressure caused by soil-borne fungi was not recorded for any of the trials. In the squash trial, spores were applied at a rate of 3.75×10¹² CFU/hectare for Bacillus amyloliquefaciens RTI301 and 0.625×10¹² CFU/hectare for Bacillus subtilis RTI477 at the time of planting via a root-zone drench, without further application via drip irrigation. ACCOMPLISH LM (LOVELAND PRODUCTS) was used as the commercial control and applied in the same manner as described for the RTI301+RTI477 combination at a rate of 2340 ml/Ha. This product contains a blend of Acidovorax facilis (1×10³ cfu/ml), Bacillus licheniformis (1×10³ cfu/ml), Bacillus subtilis (1×10³ cfu/ml), Bacillus oleronius (1×10³ cfu/ml), Bacillus marinus (1×10³ cfu/ml), Bacillus megaterium (1×10³ cfu/ml), and Rhodococcus rhodochrous(1×10³ cfu/ml). The addition of the RTI301 plus RTI477 spores resulted in an increase in both total and marketable yield for squash compared to untreated control plants in which bacterial spores were not included in the drench, as well as in comparison to the commercial control plants. Specifically, RTI301+RTI477 treated plants resulted in a total of 873.4 kg/Ha squash, as compared to 838.3 kg/Ha and 836.1 kg/Ha for the untreated control plants and the plants treated with ACCOMPLISH, respectively, representing a 4.2% and 4.5% respective increase in weight of total squash. The increase in total squash weight of the plants treated with Bacillus amyloliquefaciens RTI301 plus Bacillus subtilis RTI477 spores relative to the untreated control plants and the plants treated with the commercial standard demonstrates the positive growth effect provided by this treatment.

In the tomato trial, spores were applied at a rate of 0.625×10¹² CFU/hectare for Bacillus amyloliquefaciens RTI301 and 3.75×10¹² CFU/hectare for Bacillus subtilis RTI477 at the time of planting via a root-zone drench, followed by two drip applications of the same rate at 17 and 35 days after transplanting. ACCOMPLISH LM was used as the commercial control and applied in the same manner as described for the RTI301+RTI477 combination at a rate of 2340 ml/Ha. The addition of the RTI301 plus RTI477 spores resulted in an increase in both total and marketable yield for tomatoes compared to untreated control plants in which bacterial spores were not included in the drench and the irrigation, as well as in comparison to the commercial control plants. Specifically, RTI301+RTI477 treated plants resulted in a total of 21,824 kg/Ha marketable tomatoes, as compared to 16,765 kg/Ha and 21,420 kg/Ha for the untreated control plants and the plants treated with ACCOMPLISH, respectively, representing a 30.2% and 1.9% respective increase in weight of marketable tomatoes. The substantial increase in marketable tomato weight of the plants treated with Bacillus amyloliquefaciens RTI301 plus Bacillus subtilis RTI477 spores, especially compared to the untreated control plants, demonstrates the positive growth effect provided by this treatment.

In the pepper trial (jalapeno pepper), spores were applied at a rate of 1.25×10¹² CFU/hectare per strain of both Bacillus amyloliquefaciens RTI301 and Bacillus subtilis RTI477 at the time of planting via a root-zone drench, followed by two drip applications of the same rate at 17 and 35 days after transplanting. ACCOMPLISH LM was used as the commercial control and was applied in the same manner as described for the RTI301+RTI477 combination at a rate of 2340 ml/Ha. The addition of the RTI301 plus RTI477 spores resulted in an increase in yield for jalapeno peppers as compared to untreated control plants in which bacterial spores were not applied, as well as in comparison to the commercial control plants. Specifically, RTI301+RTI477 treated plants resulted in a total of 4154 kg/Ha marketable peppers, as compared to 3455 kg/Ha and 3930 kg/Ha for the untreated control plants and the plants treated with ACCOMPLISH, respectively, representing a 20% and a 5.7% respective increase in weight of marketable peppers. The substantial increase in marketable pepper weight of the plants treated with Bacillus amyloliquefaciens RTI301 plus Bacillus subtilis RTI477 spores relative to the untreated control plants and the plants treated with the commercial standard demonstrates the positive growth effect provided by this treatment.

Antimicrobial metabolites produced by the RTI301 and FTI477 strains are identified in EXAMPLE 12 and illustrated in FIG. 6. EXAMPLE 12 describes the investigation of the cyclic lipopeptides, Fengycins and Dehydroxyfengycins, produced by the RTI301 and RTI477 strains, and surprisingly, the identification of several previously unreported classes of these molecules. It was determined that Bacillus amyloliquefaciens RTI301 produces the previously reported Fengycin A, B and C compounds and the Dehydroxyfengycin A, B and C compounds. Unexpectantly, in addition to these known compounds, it was determined that the RTI301 strain also produces previously unidentified derivatives of these compounds where the L-isoleucine at position 8 of the cyclic peptide chain (referred to as X₃ in FIG. 6) is replaced by L-methionine. The new classes of Fengycin and Dehydroxyfengycin are referred to herein as MA, MB and MC, referring to derivatives of classes A, B and C in which the L-isoleucine at X₃ in FIG. 6 has been replaced by L-methionine. The newly identified molecules are shown in FIG. 6 and in Table IX in bold font. The newly identified Fengycin MA, MB and MC compounds were also observed for the RTI477 strain, however the corresponding Dehydroxyfengycin MA, MB and MC compounds were not observed for the RTI477 strain (see Table IX).

It was further determined that the RTI301 strain produces an additional class of Fengycin and Dehydroxyfengycin that has not been previously identified. In this class, the L-isoleucine of Fengycin B and Dehydroxyfengycin B (position X₃ in FIG. 6) is replaced by L-homo-cysteine (Hcy). These previously unidentified Fengycin and Dehydroxyfengycin metabolites are referred to herein as Fengycin H and Dehydroxyfengycin H and are shown in FIG. 6 and Table IX. The newly identified Fengycin H compound was also observed for the RTI477 strain, however the corresponding Dehydroxyfengycin H compound was not observed for the RTI477 strain (Table IX).

It was further determined that the RTI301 strain produces an additional previously unidentified class of Fengycin and Dehydroxyfengycin metabolites. In this class, the amino acid at position 4 of the cyclic peptide backbone structure (position X₁ in FIG. 6) is replaced by L-isoleucine. These previously unidentified metabolites are referred to herein as Fengicin I and Dehydroxyfengicin I and are shown in FIG. 6 and in Table IX. Both the newly identified Fengycin I and Dehydroxyfengycin I compounds were also observed for the RTI477 strain (Table IX).

Thus, in the compositions and methods of the present invention, the Bacillus amyloliquefaciens having antimicrobial properties can be a Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof. Similarly, the Bacillus subtilis having beneficial properties for plant growth and/or health can be a Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof. In the compositions and methods of the present invention, the plant can include soybean or corn and the plant growth benefit can be exhibited by increased yield.

In one embodiment, a composition is provided having two or more compatible microorganisms for benefiting plant growth and/or plant health, the composition comprising: at least one biologically pure culture of a first microorganism having antimicrobial properties and present in an amount suitable for inhibiting growth of endogenous microorganisms present in soil surrounding or living in association with a plant; and at least one biologically pure culture of a second microorganism having properties beneficial to the plant growth and/or plant health, wherein growth of the second microorganism is compatible with growth of the first microorganism, and wherein the second microorganism is present in an amount sufficient to become established and to benefit the plant growth and/or plant health, wherein application of the composition to seed of the plant, roots of the plant, or soil surrounding the plant benefits the plant growth and/or plant health. The properties of the second microorganism that are beneficial to the plant growth and/or plant health include one of increased plant yield, improved seedling vigor, improved root development, improved plant growth, improved plant health, improved appearance, improved resistance to plant pathogens, reduced pathogenic infection, or a combination thereof. The plant pathogen can include one or a combination of insects, nematodes, plant pathogenic fungi, or plant pathogenic bacteria.

In one embodiment a composition is provided for benefiting plant growth and/or plant health, the composition comprising: a biologically pure culture of Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof; and a biologically pure culture of Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof, present in an amount suitable to benefit the plant growth and/or plant health. Application of the composition to seed of the plant, roots of the plant, or soil surrounding the plant benefits plant growth and/or plant health.

As used herein, the phrase “a biologically pure culture of a bacterial strain” refers to one or a combination of: spores of the biologically pure fermentation culture of a bacterial strain, vegetative cells of the biologically pure fermentation culture of a bacterial strain, one or more products of the biologically pure fermentation culture of a bacterial strain, a culture solid of the biologically pure fermentation culture of a bacterial strain, a culture supernatant of the biologically pure fermentation culture of a bacterial strain, an extract of the biologically pure fermentation culture of the bacterial strain, and one or more metabolites of the biologically pure fermentation culture of a bacterial strain.

In one embodiment, the compositions are in the form of a planting matrix. The planting matrix can be in the form of a potting soil.

In one embodiment, the compositions further include one or a combination of a carrier, a dispersant or a yeast extract.

In one embodiment, the compositions further comprise one or a combination of a microbial, a biological, or a chemical insecticide, fungicide, nematicide, bacteriocide, herbicide, plant extract, plant growth regulator, or fertilizer present in an amount suitable to benefit plant growth and/or to confer protection against a pathogenic infection in the plant.

In one embodiment, the composition for benefiting plant growth comprises: a biologically pure culture of Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof; a biologically pure culture of Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof; and a bifenthrin insecticide.

In one embodiment, the composition for benefiting plant growth comprises: a biologically pure culture of Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof; a biologically pure culture of Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof; and a bifenthrin insecticide, wherein the composition is in a formulation compatible with a liquid fertilizer. The formulation compatible with a liquid fertilizer can comprise a hydrated aluminum-magnesium silicate and at least one dispersant. The bifenthrin insecticide can be present at a concentration ranging from 0.1 g/ml to 0.2 g/ml. The bifenthrin insecticide can be present at a concentration of about 0.1715 g/ml. The term “in a formulation compatible with a liquid fertilizer” as used throughout the specification and claims is intended to mean that the formulation is capable of dissolution or dispersion or emulsion in an aqueous solution to allow for mixing with a fertilizer for delivery to plants in a liquid formulation.

In one embodiment a method is provided for benefiting plant growth and/or plant health, the method comprising delivering to seed of a plant, roots of a plant, or soil surrounding a plant a composition comprising: at least one biologically pure culture of a first microorganism having antimicrobial properties and present in an amount suitable for inhibiting growth of endogenous microorganisms present in soil surrounding or living in association with the plant; and at least one biologically pure culture of a second microorganism having properties beneficial to the plant growth and/or plant health, wherein growth of the second microorganism is compatible with growth of the first microorganism, and wherein the second microorganism is present in an amount suitable to become established and to benefit the plant growth and/or plant health, wherein delivery of the composition benefits the plant growth and/or plant health.

In one embodiment a method is provided for benefiting plant growth and/or plant health, the method comprising delivering to seed of a plant, roots of a plant, or soil surrounding a plant a composition comprising: a biologically pure culture of a Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof; and a biologically pure culture of a Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof, wherein delivery of the composition benefits the plant growth and/or plant health.

In one embodiment a method is provided for benefiting plant growth and/or plant health, the method comprising: delivering to seed of a plant, roots of a plant, or soil surrounding a plant a combination of: a first composition comprising a biologically pure culture of a Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof; and a second composition comprising a biologically pure culture of a Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof, wherein delivery of the combination benefits the plant growth and/or plant health.

The compositions comprising the microorganisms can be in the form of a liquid, an oil dispersion, a dust, a dry wettable powder, a spreadable granule, or a dry wettable granule. The microorganisms can be present in the form of spores or vegetative cells. The composition can be in the form of a liquid and each of the Bacillus subtilis RTI477 and the Bacillus amyloliquefaciens RTI301 can be present at a concentration of from about 1.0×10⁸ CFU/ml to about 1.0×10¹² CFU/ml. The composition can be in the form of a dust, a dry wettable powder, a spreadable granule, or a dry wettable granule and each of the Bacillus subtilis RTI477 and the Bacillus amyloliquefaciens RTI301 can be present in an amount of from about 1.0×10⁸ CFU/g to about 1.0×10¹² CFU/g. The composition can be in the form of an oil dispersion and each of the Bacillus subtilis RTI477 and the Bacillus amyloliquefaciens RTI301 can be present at a concentration of from about 1.0×10⁸ CFU/ml to about 1.0×10¹² CFU/ml.

The compositions comprising the microorganisms may further comprise one or a combination of a carrier, a dispersant or a yeast extract.

In one embodiment, a plant seed is provided that is coated with a composition having two or more compatible microorganisms for benefiting plant growth and/or plant health. The coating composition includes spores of at least one biologically pure culture of a first microorganism having antimicrobial properties and present in an amount suitable for inhibiting growth of endogenous microorganisms present in soil surrounding or living in association with a plant. The composition also includes spores of at least one biologically pure culture of a second microorganism having properties beneficial to plant growth and/or plant health, wherein growth of the second microorganism is compatible with growth of the first microorganism, and wherein the second microorganism is present in an amount sufficient to become established and to benefit the plant growth and/or plant health.

In one embodiment a plant seed is provided coated with a composition for benefiting plant growth and/or plant health, the composition comprising: spores of a biologically pure culture of Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof; and spores of a biologically pure culture of Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof, present in an amount suitable to benefit the plant growth and/or plant health.

In one embodiment, the Bacillus subtilis RTI477 and the Bacillus amyloliquefaciens RTI301 are each present in an amount ranging from about 1.0×10² CFU/seed to about 1.0×10⁹ CFU/seed.

In one embodiment, the plant seed further comprises one or a combination of a microbial, a biological, or a chemical insecticide, fungicide, nematicide, bacteriocide, herbicide, plant extract, plant growth regulator, or fertilizer present in an amount suitable to benefit plant growth and/or to confer protection against a pathogenic infection in the plant. In one embodiment, the insecticide comprises bifenthrin.

In one embodiment, a plant seed is provided, wherein the plant seed is coated with a composition for benefiting plant growth and/or plant health, the composition comprising: spores of a biologically pure culture of Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof; spores of a biologically pure culture of Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof; and a bifenthrin insecticide.

In one embodiment, a method is provided for benefiting plant growth and/or plant health, the method comprising planting a seed of a plant in a suitable growth medium, wherein the seed has been coated with a composition comprising spores of at least one biologically pure culture of a first microorganism having antimicrobial properties and present in an amount suitable for inhibiting growth of endogenous microorganisms present in soil surrounding or living in association with the plant; and spores of at least one biologically pure culture of a second microorganism having plant growth and/or plant health promoting properties, wherein growth of the second microorganism is compatible with growth of the first microorganism, and wherein the second microorganism is present in an amount suitable to become established and to benefit the plant growth and/or plant health.

In one embodiment, a method is provided for benefiting plant growth and/or plant health, the method comprising planting a seed of a plant in a suitable growth medium, wherein the seed has been coated with a composition comprising: spores of a biologically pure culture of Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof; and spores of a biologically pure culture of Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof, wherein the coating comprising the spores of the RTI301 and the RTI477 benefits the plant growth and/or plant health.

The coated seed of the present invention can be a seed from a wide variety of plants including, for example, comprises the seed of monocots, dicots, Cereals, Corn, Sweet Corn, Popcorn, Seed Corn, Silage Corn, Field Corn, Rice, Wheat, Barley, Sorghum, Brassica Vegetables, Broccoli, Cabbage, Cauliflower, Brussels Sprouts, Collards, Kale, Mustard Greens, Kohlrabi, Bulb Vegetables, Onion, Garlic, Shallots, Fruiting Vegetables, Pepper, Tomato, Ground Cherry, Tomatillo, Okra, Grape, Herbs/Spices, Cucurbit Vegetables, Cucumber, Cantaloupe, Melon, Muskmelon, Squash, Watermelon, Pumpkin, Eggplant, Leafy Vegetables, Lettuce, Celery, Spinach, Parsley, Radicchio, Legumes/Vegetables (succulent and dried beans and peas), Beans, Green beans, Snap beans, Shell beans, Soybeans, Dry Beans, Garbanzo beans, Lima beans, Peas, Chick peas, Split peas, Lentils, Oil Seed Crops, Canola, Castor, Cotton, Flax, Peanut, Rapeseed, Safflower, Sesame, Sunflower, Soybean, Root/Tuber and Corm Vegetables, Carrot, Potato, Sweet Potato, Beets, Ginger, Horseradish, Radish, Ginseng, Turnip, sugarcane, sugarbeet, Grass, and Turf grass.

The coated plant seed can be corn or soybean and the plant growth benefit can be exhibited by increased yield.

For the coated plant seed, the properties of the second microorganism beneficial to plant growth and/or plant health include one or more of increased yield, improved seedling vigor, improved root development, improved plant growth, improved plant health, improved appearance, improved resistance to plant pathogens, or reduced pathogenic infection, or a combination thereof. The plant pathogen can include one or a combination of insects, nematodes, plant pathogenic fungi, or plant pathogenic bacteria.

The first and second microorganisms of the composition coating the plant seed can be Bacillus spp. microorganisms. The growth of the second microorganism can be faster than that of the first microorganism and the second microorganism can be characterized by a swarming and high motility phenotype. The second microorganism can be a Bacillus subtilis. The first microorganism can be a Bacillus amyloliquefaciens and the second microorganism can be a Bacillus subtilis. The Bacillus amyloliquefaciens can be a Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof. The Bacillus subtilis can be a Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof. The composition coated onto the plant seed can include an amount of spores of each of the first microorganism and the second microorganism from about 1.0×10² CFU/seed to about 1.0×10⁹ CFU/seed.

In one embodiment a method is provided for benefiting plant growth and/or plant health, the method comprising planting a seed of a plant in a suitable growth medium, wherein the seed has been coated with a composition comprising: spores of a biologically pure culture of Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof; and spores of a biologically pure culture of Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof, present in an amount suitable to benefit the plant growth and/or plant health.

In one embodiment a composition is provided for benefiting plant growth and/or plant health, the composition comprising: one or more chemical active agents having one or both of antibacterial or antifungal properties and present in an amount suitable for inhibiting growth of endogenous microorganisms present in soil surrounding or living in association with a plant; and at least one biologically pure culture of a microorganism having properties beneficial to the plant growth and/or plant health. Growth of the microorganism is compatible with the chemical active agent, and the microorganism is present in an amount suitable to become established and to benefit the plant growth and/or plant health. Application of the composition to seed of the plant, roots of the plant, or soil surrounding the plant benefits the plant growth and/or plant health.

In one embodiment, a method is provided for benefiting plant growth and/or plant health, the method comprising delivering to seed of a plant, roots of a plant, or soil surrounding a plant a combination of: one or more chemical active agents having one or both of antibacterial or antifungal properties present in an amount suitable for inhibiting growth of endogenous microorganisms present in soil surrounding or living in association with the plant; and a composition comprising at least one biologically pure culture of a microorganism having properties beneficial to the plant growth and/or plant health. Growth of the microorganism is compatible with the chemical active agent or, in the case of incompatibility, the microorganism is delivered subsequent to delivery of the chemical active agent. The microorganism is present in an amount suitable to become established and to benefit the plant growth and/or plant health, such that delivery of the combination of the chemical active agent and the microorganism benefits the plant growth and/or plant health. In the case where the one or more chemical active agents and the microorganism are compatible, the one or more chemical active agents can be formulated together with the composition that includes the microorganism. Delivery of the combination of the chemical active agent and the microorganism to seed of the plant, roots of the plant, or soil surrounding the plant benefits plant growth and/or plant health.

For the composition and method including one or more chemical active agents, the properties of the microorganism beneficial to plant growth and/or plant health can include increased yield, improved seedling vigor, improved root development, improved plant growth, improved plant health, improved appearance, improved resistance to plant pathogens, reduced pathogenic infection, or a combination thereof. The plant pathogens can include one or a combination of insects, nematodes, plant pathogenic fungi, or plant pathogenic bacteria.

The one or more chemical active agents for creating the niche can include, for example, but are not limited to strobilurine, a triazole, flutriafol, tebuconazole, prothiaconazole, expoxyconazole, fluopyram, chlorothalonil, thiophanate-methyl, a copper-based fungicide, copper hydroxide fungicide, an EDBC-based fungicide, mancozeb, a succinase dehydrogenase (SDHI) fungicide, bixafen, iprodione, dimethomorph, or valifenalate. In another example, the one or more chemical active agents can include a fumigant such as, for example, chloropicrin, Dazomet, 1,3-dichloropropene (Telone), dimethyl disulfide, metam sodium/potassium, methyl bromide.

The composition can be in the form of a liquid, an oil dispersion, a dust, a dry wettable powder, a spreadable granule, or a dry wettable granule. The beneficial microorganism can be present in the form of spores or vegetative cells. The beneficial microorganism can be a Bacillus spp. The beneficial microorganism can be a Bacillus subtilis. The microorganism can be a Bacillus subtilis characterized by a swarming and high motility phenotype. The microorganism can be a Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof. The composition can be in the form of a liquid and the beneficial microorganism can be Bacillus subtilis RTI477 present at a concentration of from about 1.0×10⁸ CFU/ml to about 1.0×10¹² CFU/ml. The composition can be in the form of a dust, a dry wettable powder, a spreadable granule, or a dry wettable granule and the Bacillus subtilis RTI477 can be present in an amount of from about 1.0×10⁸ CFU/g to about 1.0×10¹² CFU/g. The composition can be in the form of an oil dispersion and the Bacillus subtilis RTI477 can be present at a concentration of from about 1.0×10⁸ CFU/ml to about 1.0×10¹² CFU/ml.

In the compositions and methods having two or more compatible microorganisms of the present invention for benefiting plant growth and/or plant health, the compositions can further include one or a combination of a microbial, a biological, or a chemical insecticide, fungicide, nematicide, bacteriocide, herbicide, plant extract, plant growth regulator, or fertilizer present in an amount suitable to benefit plant growth and/or to confer protection against a pathogenic infection in the plant.

In one embodiment, the fungicide can include an extract from Lupinus albus doce. In one embodiment, the fungicide can include a BLAD polypeptide. The BLAD polypeptide can be a fragment of the naturally occurring seed storage protein from sweet lupine (Lupinus albus doce) that acts on susceptible fungal pathogens by causing damage to the fungal cell wall and disrupting the inner cell membrane. The compositions can include about 20% of the BLAD polypeptide.

In one embodiment, the insecticide can comprise bifenthrin. The nematicide can comprise cadusafos. The composition can be formulated as a liquid, a powder, a wettable dissolvable granule, or as spreadable granules. The insecticide can comprise bifenthrin and clothianidin. The insecticide can comprise bifenthrin and clothianidin and the composition can be formulated for compatibility with a liquid fertilizer. The insecticide can comprise bifenthrin or zeta-cypermethrin.

The nematicide can comprise cadusafos. The insecticide can comprise bifenthrin and clothianidin. The composition can be formulated as a liquid and the insecticide can comprise bifenthrin or zeta-cypermethrin.

In one embodiment, the method can further include applying a liquid fertilizer to: soil or growth medium surrounding the plant; soil or growth medium before sowing seed of the plant in the soil or growth medium; or soil or growth medium before planting the plant in the soil or growth medium.

In an embodiment, the bifenthrin composition can comprise: bifenthrin; a hydrated aluminum-magnesium silicate; and at least one dispersant selected from a sucrose ester, a lignosulfonate, an alkylpolyglycoside, a naphthalenesulfonic acid formaldehyde condensate and a phosphate ester.

The bifenthrin can be preferably present in a concentration of from 1.0% by weight to 35% by weight, more particularly, from 15% by weight to 25% by weight based upon the total weight of all components in the composition. The bifenthrin insecticide composition can be present in the liquid formulation at a concentration ranging from 0.1 g/ml to 0.2 g/ml. The bifenthrin insecticide may be present in the liquid formulation at a concentration of about 0.1715 g/ml.

The dispersant or dispersants can preferably be present in a total concentration of from about 0.02% by weight to about 20% by weight based upon the total weight of all components in the composition.

In some embodiments, the hydrated aluminum-magnesium silicate may be selected from the group consisting of montmorillonite and attapulgite.

In some embodiments, the phosphate ester may be selected from a nonyl phenol phosphate ester and a tridecyl alcohol ethoxylated phosphate potassium salt.

Other embodiments may further include at least one of an anti-freeze agent, an anti-foam agent and a biocide.

In one embodiment a composition is provided for benefiting plant growth, the composition comprising: a biologically pure culture of Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof; a biologically pure culture of Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof; and an insecticide, wherein the composition is in a formulation compatible with a liquid fertilizer. The insecticide can be one or a combination of pyrethroids, bifenthrin, tefluthrin, zeta-cypermethrin, organophosphates, chlorethoxyfos, chlorpyrifos, tebupirimfos, cyfluthrin, fiproles, fipronil, nicotinoids, or clothianidin. The insecticide can include bifenthrin. The composition can include a bifenthrin insecticide and a hydrated aluminum-magnesium silicate and at least one dispersant. The bifenthrin insecticide can be present at a concentration ranging from 0.1 g/ml to 0.2 g/ml. The bifenthrin insecticide can be present at a concentration of about 0.1715 g/ml.

In addition, suitable insecticides, herbicides, fungicides, and nematicides of the compositions and methods of the present invention can include the following:

Insecticides: A0) various insecticides, including agrigata, al-phosphide, amblyseius, aphelinus, aphidius, aphidoletes, artimisinin, autographa californica NPV, azocyclotin, Bacillus subtilis, Bacillus thuringiensis-spp. aizawai, Bacillus thuringiensis spp. kurstaki, Bacillus thuringiensis, Beauveria, Beauveria bassiana, betacyfluthrin, biologicals, bisultap, brofluthrinate, bromophos-e, bromopropylate, Bt-Corn-GM, Bt-Soya-GM, capsaicin, cartap, celastrus-extract, chlorantraniliprole, chlorbenzuron, chlorethoxyfos, chlorfluazuron, chlorpyrifos-e, cnidiadin, cryolite, cyanophos, cyantraniliprole, cyhalothrin, cyhexatin, cypermethrin, dacnusa, DCIP, dichloropropene, dicofol, diglyphus, diglyphus+dacnusa, dimethacarb, dithioether, dodecyl-acetate, emamectin, encarsia, EPN, eretmocerus, ethylene-dibromide, eucalyptol, fatty-acids, fatty-acids/salts, fenazaquin, fenobucarb (BPMC), fenpyroximate, flubrocythrinate, flufenzine, formetanate, formothion, furathiocarb, gamma-cyhalothrin, garlic-juice, granulosis-virus, harmonia, heliothis armigera NPV, inactive bacterium, indol-3-ylbutyric acid, iodomethane, iron, isocarbofos, isofenphos, isofenphos-m, isoprocarb, isothioate, kaolin, lindane, liuyangmycin, matrine, mephosfolan, metaldehyde, metarhizium-anisopliae, methamidophos, metolcarb (MTMC), mineral-oil, mirex, m-isothiocyanate, monosultap, myrothecium verrucaria, naled, neochrysocharis formosa, nicotine, nicotinoids, oil, oleic-acid, omethoate, orius, oxymatrine, paecilomyces, paraffin-oil, parathion-e, pasteuria, petroleum-oil, pheromones, phosphorus-acid, photorhabdus, phoxim, phytoseiulus, pirimiphos-e, plant-oil, plutella xylostella GV, polyhedrosis-virus, polyphenol-extracts, potassium-oleate, profenofos, prosuler, prothiofos, pyraclofos, pyrethrins, pyridaphenthion, pyrimidifen, pyriproxifen, quillay-extract, quinomethionate, rape-oil, rotenone, saponin, saponozit, sodium-compounds, sodium-fluosilicate, starch, steinernema, streptomyces, sulfluramid, sulphur, tebupirimfos, tefluthrin, temephos, tetradifon, thiofanox, thiometon, transgenics (e.g., Cry3Bb1), triazamate, trichoderma, trichogramma, triflumuron, verticillium, vertrine, isomeric insecticides (e.g., kappa-bifenthrin, kappa-tefluthrin), dichoromezotiaz, broflanilide, pyraziflumid; A1) the class of carbamates, including aldicarb, alanycarb, benfuracarb, carbaryl, carbofuran, carbosulfan, methiocarb, methomyl, oxamyl, pirimicarb, propoxur and thiodicarb; A2) the class of organophosphates, including acephate, azinphos-ethyl, azinphos-methyl, chlorfenvinphos, chlorpyrifos, chlorpyrifos-methyl, demeton-S-methyl, diazinon, dichlorvos/DDVP, dicrotophos, dimethoate, disulfoton, ethion, fenitrothion, fenthion, isoxathion, malathion, methamidaphos, methidathion, mevinphos, monocrotophos, oxymethoate, oxydemeton-methyl, parathion, parathion-methyl, phenthoate, phorate, phosalone, phosmet, phosphamidon, pirimiphos-methyl, quinalphos, terbufos, tetrachlorvinphos, triazophos and trichlorfon; A3) the class of cyclodiene organochlorine compounds such as endosulfan; A4) the class of fiproles, including ethiprole, fipronil, pyrafluprole and pyriprole; A5) the class of neonicotinoids, including acetamiprid, clothianidin, dinotefuran, imidacloprid, nitenpyram, thiacloprid and thiamethoxam; A6) the class of spinosyns such as spinosad and spinetoram; A7) chloride channel activators from the class of mectins, including abamectin, emamectin benzoate, ivermectin, lepimectin and milbemectin; A8) juvenile hormone mimics such as hydroprene, kinoprene, methoprene, fenoxycarb and pyriproxyfen; A9) selective homopteran feeding blockers such as pymetrozine, flonicamid and pyrifluquinazon; A10) mite growth inhibitors such as clofentezine, hexythiazox and etoxazole; A11) inhibitors of mitochondrial ATP synthase such as diafenthiuron, fenbutatin oxide and propargite; uncouplers of oxidative phosphorylation such as chlorfenapyr; A12) nicotinic acetylcholine receptor channel blockers such as bensultap, cartap hydrochloride, thiocyclam and thiosultap sodium; A13) inhibitors of the chitin biosynthesis type 0 from the benzoylurea class, including bistrifluron, diflubenzuron, flufenoxuron, hexaflumuron, lufenuron, novaluron and teflubenzuron; A14) inhibitors of the chitin biosynthesis type 1 such as buprofezin; A15) moulting disrupters such as cyromazine; A16) ecdyson receptor agonists such as methoxyfenozide, tebufenozide, halofenozide and chromafenozide; A17) octopamin receptor agonists such as amitraz; A18) mitochondrial complex electron transport inhibitors pyridaben, tebufenpyrad, tolfenpyrad, flufenerim, cyenopyrafen, cyflumetofen, hydramethylnon, acequinocyl or fluacrypyrim; A19) voltage-dependent sodium channel blockers such as indoxacarb and metaflumizone; A20) inhibitors of the lipid synthesis such as spirodiclofen, spiromesifen and spirotetramat; A21) ryanodine receptor-modulators from the class of diamides, including flubendiamide, the phthalamide compounds (R)-3-Chlor-N1-{2-methyl-4-[1,2,2,2-tetrafluor-1-(trifluormethyl)ethyl]phenyl}-N2-(1-methyl-2-methylsulfonylethyl)phthalamid and (S)-3-Chlor-N1-{2-methyl-4-[1,2,2,2-tetrafluor-1-(trifluormethyl)ethyl]phenyl}-N2-(1-methyl-2-methylsulfonylethyl)phthalamid, chloranthraniliprole and cy-anthraniliprole; A22) compounds of unknown or uncertain mode of action such as azadirachtin, amidoflumet, bifenazate, fluensulfone, piperonyl butoxide, pyridalyl, sulfoxaflor; or A23) sodium channel modulators from the class of pyrethroids, including acrinathrin, allethrin, bifenthrin, cyfluthrin, lambda-cyhalothrin, cypermethrin, alpha-cypermethrin, beta-cypermethrin, zeta-cypermethrin, deltamethrin, esfenvalerate, etofenprox, fenpropathrin, fenvalerate, flucythrinate, tau-fluvalinate, permethrin, silafluofen and tralomethrin.

Fungicides: B0) benzovindiflupyr, anitiperonosporic, ametoctradin, amisulbrom, copper salts (e.g., copper hydroxide, copper oxychloride, copper sulfate, copper persulfate), boscalid, thiflumazide, flutianil, furalaxyl, thiabendazole, benodanil, mepronil, isofetamid, fenfuram, bixafen, fluxapyroxad, penflufen, sedaxane, coumoxystrobin, enoxastrobin, flufenoxystrobin, pyraoxystrobin, pyrametostrobin, triclopyricarb, fenaminstrobin, metominostrobin, pyribencarb, meptyldinocap, fentin acetate, fentin chloride, fentin hydroxide, oxytetracycline, chlozolinate, chloroneb, tecnazene, etridiazole, iodocarb, prothiocarb, Bacillus subtilis syn., Bacillus amyloliquefaciens (e.g., strains QST 713, FZB24, MB1600, D747), extract from Melaleuca alternifolia, pyrisoxazole, oxpoconazole, etaconazole, fenpyrazamine, naftifine, terbinafine, validamycin, pyrimorph, valifenalate, fthalide, probenazole, isotianil, laminarin, extract from Reynoutria sachalinensis, phosphorous acid and salts, teclofthalam, triazoxide, pyriofenone, organic oils, potassium bicarbonate, chlorothalonil, fluoroimide; B1) azoles, including bitertanol, bromuconazole, cyproconazole, difenoconazole, diniconazole, enilconazole, epoxiconazole, fluquinconazole, fenbuconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, metconazole, myclobutanil, penconazole, propiconazole, prothioconazole, simeconazole, triadimefon, triadimenol, tebuconazole, tetraconazole, triticonazole, prochloraz, pefurazoate, imazalil, triflumizole, cyazofamid, benomyl, carbendazim, thia-bendazole, fuberidazole, ethaboxam, etridiazole and hymexazole, azaconazole, diniconazole-M, oxpoconazol, paclobutrazol, uniconazol, 1-(4-chloro-phenyl)-2-([1,2,4]triazol-1-yl)-cycloheptanol and imazalilsulfphate; B2) strobilurins, including azoxystrobin, dimoxystrobin, enestroburin, fluoxastrobin, kresoxim-methyl, methominostrobin, orysastrobin, picoxystrobin, pyraclostrobin, trifloxystrobin, enestroburin, methyl (2-chloro-5-[1-(3-methylbenzyloxyimino)ethyl]benzyl)carbamate, methyl (2-chloro-5-[1-(6-methylpyridin-2-ylmethoxyimino)ethyl]benzyl)carbamate and methyl 2-(ortho-(2,5-dimethylphenyloxymethylene)-phenyl)-3-methoxyacrylate, 2-(2-(6-(3-chloro-2-methyl-phenoxy)-5-fluoro-pyrimidin-4-yloxy)-phenyl)-2-methoxyimino-N-methyl-acetamide and 3-methoxy-2-(2-(N-(4-methoxy-phenyl)-cyclopropanecarboximidoylsulfanylmethyl)-phenyl)-acrylic acid methyl ester; B3) carboxamides, including carboxin, benalaxyl, benalaxyl-M, fenhexamid, flutolanil, furametpyr, mepronil, metalaxyl, mefenoxam, ofurace, oxadixyl, oxycarboxin, penthiopyrad, isopyrazam, thifluzamide, tiadinil, 3,4-dichloro-N-(2-cyanophenyl)isothiazole-5-carboxamide, dimethomorph, flumorph, flumetover, fluopicolide (picobenzamid), zoxamide, carpropamid, diclocymet, mandipropamid, N-(2-(4-[3-(4-chlorophenyl)prop-2-ynyloxy]-3-methoxyphenyl)ethyl)-2-methanesulfonyl-amino-3-methylbutyramide, N-(2-(4-[3-(4-chloro-phenyl)prop-2-ynyloxy]-3-methoxy-phenyl)ethyl)-2-ethanesulfonylamino-3-methylbutyramide, methyl 3-(4-chlorophenyl)-3-(2-isopropoxycarbonylamino-3-methyl-butyrylamino)propionate, N-(4′-bromobiphenyl-2-yl)-4-difluoromethyl̂-methylthiazole-δ-carboxamide, N-(4′-trifluoromethyl-biphenyl-2-yl)-4-difluoromethyl-2-methylthiazole-5-carboxamide, N-(4′-chloro-3′-fluorobiphenyl-2-yl)-4-difluoromethyl-2-methyl-thiazole-5-carboxamide, N-(3\4′-dichloro-4-fluorobiphenyl-2-yl)-3-difluoro-methyl-1-methyl-pyrazole-4-carboxamide, N-(3′,4′-dichloro-5-fluorobiphenyl-2-yl)-3-difluoromethyl-1-methylpyrazole-4-carboxamide, N-(2-cyano-phenyl)-3,4-dichloroisothiazole-5-carboxamide, 2-amino-4-methyl-thiazole-5-carboxanilide, 2-chloro-N-(1,1,3-trimethyl-indan-4-yl)-nicotinamide, N-(2-(1,3-dimethylbutyl)-phenyl)-1,3-dimethyl-5-fluoro-1 H-pyrazole-4-carboxamide, N-(4′-chloro-3′,5-difluoro-biphenyl-2-yl)-3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxamide, N-(4′-chloro-3′,5-difluoro-biphenyl-2-yl)-3-trifluoromethyl-1-methyl-1H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-5-fluoro-biphenyl-2-yl)-3-trifluoromethyl-1-methyl-1H-pyrazole-4-carboxamide, N-(3′,5-difluoro-4′-methyl-biphenyl-2-yl)-3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxamide, N-(3′,5-difluoro-4′-methyl-biphenyl-2-yl)-3-trifluoromethyl-1-methyl-1H-pyrazole-4-carboxamide, N-(cis-2-bicyclopropyl-2-yl-phenyl)-3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxamide, N-(trans-2-bicyclopropyl-2-yl-phenyl)-3-difluoro-methyl-1-methyl-1 H-pyrazole-4-carboxamide, fluopyram, N-(3-ethyl-3,5-5-trimethyl-cyclohexyl)-3-formylamino-2-hydroxy-benzamide, oxytetracyclin, silthiofam, N-(6-methoxy-pyridin-3-yl) cyclopropanecarboxamide, 2-iodo-N-phenyl-benzamide, N-(2-bicyclo-propyl-2-yl-phenyl)-3-difluormethyl-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-1,3-dimethylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-1,3-dimethyl-5-fluoropyrazol-4-yl-carboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-5-chloro-1,3-dimethylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-3-fluoromethyl-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-3-(chlorofluoromethyl)-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-3-difluoromethyl-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-3-difluoromethyl-5-fluoro-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-5-chloro-3-difluoromethyl-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-3-(chlorodifluoromethyl)-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-1-methyl-3-trifluoromethylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-5-fluoro-1-methyl-3-trifluoromethylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-5-chloro-1-methyl-3-trifluoromethylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-1,3-dimethylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-1,3-dimethyl-5-fluoropyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-5-chloro-1,3-dimethylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-3-fluoromethyl-1-methylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-3-(chlorofluoromethyl)-1-methylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-3-difluoromethyl-1-methylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-3-difluoromethyl-5-fluoro-1-methylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-5-chloro-3-difluoromethyl-1-methylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-3-(chlorodifluoromethyl)-1-methylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-1-methyl-3-trifluoromethylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-5-fluoro-1-methyl-3-trifluoromethylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-5-chloro-1-methyl-3-trifluoromethylpyrazol-4-ylcarboxamide, N-(3′,4′-dichloro-3-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-3-fluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-difluoro-3-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxamide, N-(3′,4′-difluoro-3-fluorobiphenyl-2-yl)-1-methyl-S-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′-chloro-4′-fluoro-3-fluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-4-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-difluoro-4-fluorobiphenyl-2-yl)-1-methyl-S-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-4-fluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-difluoro-4-fluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′-chloro-4′-fluoro-4-fluorobiphenyl-2-yl)-1-methyl-S-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-5-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-difluoro-5-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-5-fluorobiphenyl-2-yl)-1-methyl-S-difluoromethyl-1 H-pyrazole-carboxamide, N-(3′,4′-difluoro-5-fluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-5-fluorobiphenyl-2-yl)-1,3-dimethyl-1 H-pyrazole-4-carboxamide, N-(3′-chloro-4′-fluoro-5-fluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(4′-fluoro-4-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(4′-fluoro-5-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxamide, N-(4′-chloro-5-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(4′-methyl-5-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(4′-fluoro-5-fluorobiphenyl-2-yl)-1,3-dimethyl-1 H-pyrazole-4-carboxamide, N-(4′-chloro-5-fluorobiphenyl-2-yl)-1,3-dimethyl-1 H-pyrazole-4-carboxamide, N-(4′-methyl-5-fluorobiphenyl-2-yl)-1,3-dimethyl-1 H-pyrazole-4-carboxamide, N-(4′-fluoro-6-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(4′-chloro-6-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-[2-(1,1,2,3,3,3-hexafluoropropoxy)-phenyl]-3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxamide, N-[4′-(trifluoromethylthio)-biphenyl-2-yl]-3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxamide and N-[4′-(trifluoromethylthio)-biphenyl-2-yl]-1-methyl-3-trifluoromethyl-1-methyl-1H-pyrazole-4-carboxamide; B4) heterocyclic compounds, including fluazinam, pyrifenox, bupirimate, cyprodinil, fenarimol, ferimzone, mepanipyrim, nuarimol, pyrimethanil, triforine, fenpiclonil, fludioxonil, aldimorph, dodemorph, fenpropimorph, tridemorph, fenpropidin, iprodione, procymidone, vinclozolin, famoxadone, fenamidone, octhilinone, proben-azole, 5-chloro-7-(4-methyl-piperidin-1-yl)-6-(2,4,6-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidine, anilazine, diclomezine, pyroquilon, proquinazid, tricyclazole, 2-butoxy-6-iodo-3-propylchromen-4-one, acibenzolar-S-methyl, captafol, captan, dazomet, folpet, fenoxanil, quinoxyfen, N,N-dimethyl-3-(3-bromo-6-fluoro-2-methylindole-1-sulfonyl)-[1,2,4]triazole-1-sulfonamide, 5-ethyl-6-octyl-[1,2,4]triazolo[1,5-a]pyrimidin-2,7-diamine, 2,3,5,6-tetrachloro-4-methanesulfonyl-pyridine, 3,4,5-trichloro-pyridine-2,6-di-carbonitrile, N-(1-(5-bromo-3-chloro-pyridin-2-yl)-ethyl)-2,4-dichloro-nicotinamide, N-((5-bromo-3-chloro pyridin-2-yl)-methyl)-2,4-dichloro-nicotinamide, diflumetorim, nitrapyrin, dodemorphacetate, fluoroimid, blasticidin-S, chinomethionat, debacarb, difenzoquat, difenzoquat-methylsulphat, oxolinic acid and piperalin; B5) carbamates, including mancozeb, maneb, metam, methasulphocarb, metiram, ferbam, propineb, thiram, zineb, ziram, diethofencarb, iprovalicarb, benthiavalicarb, propamocarb, propamocarb hydrochlorid, 4-fluorophenyl N-(1-(1-(4-cyanophenyl)-ethanesulfonyl)but-2-yl)carbamate, methyl 3-(4-chloro-phenyl)-3-(2-isopropoxycarbonylamino-3-methyl-butyrylamino)propanoate; or B6) other fungicides, including guanidine, dodine, dodine free base, iminoctadine, guazatine, antibiotics: kasugamycin, oxytetracyclin and its salts, streptomycin, polyoxin, validamycin A, nitrophenyl derivatives: binapacryl, dinocap, dinobuton, sulfur-containing heterocyclyl compounds: dithianon, isoprothiolane, organometallic compounds: fentin salts, organophosphorus compounds: edifenphos, iprobenfos, fosetyl, fosetyl-aluminum, phosphorous acid and its salts, pyrazophos, tolclofos-methyl, organochlorine compounds: dichlofluanid, flusulfamide, hexachloro-benzene, phthalide, pencycuron, quintozene, thiophanate, thiophanate-methyl, tolylfluanid, others: cyflufenamid, cymoxanil, dimethirimol, ethirimol, furalaxyl, metrafenone and spiroxamine, guazatine-acetate, iminoc-tadine-triacetate, iminoctadine-tris(albesilate), kasugamycin hydrochloride hydrate, dichlorophen, pentachlorophenol and its salts, N-(4-chloro-2-nitro-phenyl)-N-ethyl-4-methyl-benzenesulfonamide, dicloran, nitrothal-isopropyl, tecnazen, biphenyl, bronopol, diphenylamine, mildiomycin, oxincopper, prohexadione calcium, N-(cyclopropylmethoxyimino-(6-difluoromethoxy-2,3-difluoro-phenyl)-methyl)-2-phenyl acetamide, N′-(4-(4-chloro-3-trifluoromethyl-phenoxy)-2,5-dimethyl-phenyl)-N-ethyl-N-methyl formamidine, N′-(4-(4-fluoro-3-trifluoromethyl-phenoxy)-2,5-dimethyl-phenyl)-N-ethyl-N-methyl formamidine, N′-(2-methyl-5-trifluormethyl-4-(3-trimethylsilanyl-propoxy)-phenyl)-N-ethyl-N-methylformamidine and N′-(5-difluormethyl-2-methyl-4-(3-trimethylsilanyl-propoxy)-phenyl)-N-ethyl-N-methyl formamidine.

Herbicides: C1) acetyl-CoA carboxylase inhibitors (ACC), for example cyclohexenone oxime ethers, such as alloxydim, clethodim, cloproxydim, cycloxydim, sethoxydim, tralkoxydim, butroxydim, clefoxydim or tepraloxydim; phenoxyphenoxypropionic esters, such as clodinafop-propargyl, cyhalofop-butyl, diclofop-methyl, fenoxaprop-ethyl, fenoxaprop-P-ethyl, fenthiapropethyl, fluazifop-butyl, fluazifop-P-butyl, haloxyfop-ethoxyethyl, haloxyfop-methyl, haloxyfop-P-methyl, isoxapyrifop, propaquizafop, quizalofop-ethyl, quizalofop-P-ethyl or quizalofop-tefuryl; or arylaminopropionic acids, such as flamprop-methyl or flamprop-isopropyl; C2 acetolactate synthase inhibitors (ALS), for example imidazolinones, such as imazapyr, imazaquin, imazamethabenz-methyl (imazame), imazamox, imazapic or imazethapyr; pyrimidyl ethers, such as pyrithiobac-acid, pyrithiobac-sodium, bispyribac-sodium. KIH-6127 or pyribenzoxym; sulfonamides, such as florasulam, flumetsulam or metosulam; or sulfonylureas, such as amidosulfuron, azimsulfuron, bensulfuron-methyl, chlorimuron-ethyl, chlorsulfuron, cinosulfuron, cyclosulfamuron, ethametsulfuron-methyl, ethoxysulfuron, flazasulfuron, halosulfuron-methyl, imazosulfuron, metsulfuron-methyl, nicosulfuron, primisulfuron-methyl, prosulfuron, pyrazosulfuron-ethyl, rimsulfuron, sulfometuron-methyl, thifensulfuron-methyl, triasulfuron, tribenuron-methyl, triflusulfuron-methyl, tritosulfuron, sulfosulfuron, foramsulfuron or iodosulfuron; C3) amides, for example allidochlor (CDAA), benzoylprop-ethyl, bromobutide, chiorthiamid. diphenamid, etobenzanidibenzchlomet), fluthiamide, fosamin or monalide; C4) auxin herbicides, for example pyridinecarboxylic acids, such as clopyralid or picloram; or 2,4-D or benazolin; C5) auxin transport inhibitors, for example naptalame or diflufenzopyr; C6) carotenoid biosynthesis inhibitors, for example benzofenap, clomazone (dimethazone), diflufenican, fluorochloridone, fluridone, pyrazolynate, pyrazoxyfen, isoxaflutole, isoxachlortole, mesotrione, sulcotrione (chlormesulone), ketospiradox, flurtamone, norflurazon or amitrol; C7) enolpyruvylshikimate-3-phosphate synthase inhibitors (EPSPS), for example glyphosate or sulfosate; C8) glutamine synthetase inhibitors, for example bilanafos (bialaphos) or glufosinate-ammonium; C9) lipid biosynthesis inhibitors, for example anilides, such as anilofos or mefenacet; chloroacetanilides, such as dimethenamid, S-dimethenamid, acetochlor, alachlor, butachlor, butenachlor, diethatyl-ethyl, dimethachlor, metazachlor, metolachlor, S-metolachlor, pretilachlor, propachlor, prynachlor, terbuchlor, thenylchlor or xylachlor; thioureas, such as butylate, cycloate, di-allate, dimepiperate, EPTC. esprocarb, molinate, pebulate, prosulfocarb, thiobencarb (benthiocarb), tri-allate or vemolate; or benfuresate or perfluidone; C10) mitosis inhibitors, for example carbamates, such as asulam, carbetamid, chlorpropham, orbencarb, pronamid (propyzamid), propham or tiocarbazil; dinitroanilines, such as benefin, butralin, dinitramin, ethalfluralin, fluchloralin, oryzalin, pendimethalin, prodiamine or trifluralin; pyridines, such as dithiopyr or thiazopyr; or butamifos, chlorthal-dimethyl (DCPA) or maleic hydrazide; C11) protoporphyrinogen IX oxidase inhibitors, for example diphenyl ethers, such as acifluorfen, acifluorfen-sodium, aclonifen, bifenox, chlomitrofen (CNP), ethoxyfen, fluorodifen, fluoroglycofen-ethyl, fomesafen, furyloxyfen, lactofen, nitrofen, nitrofluorfen or oxyfluorfen; oxadiazoles, such as oxadiargyl or oxadiazon; cyclic imides, such as azafenidin, butafenacil, carfentrazone-ethyl, cinidon-ethyl, flumiclorac-pentyl, flumioxazin, flumipropyn, flupropacil, fluthiacet-methyl, sulfentrazone or thidiazimin; or pyrazoles, such as ET-751.JV 485 or nipyraclofen; C12) photosynthesis inhibitors, for example propanil, pyridate or pyridafol; benzothiadiazinones, such as bentazone; dinitrophenols, for example bromofenoxim, dinoseb, dinoseb-acetate, dinoterb or DNOC; dipyridylenes, such as cyperquat-chloride, difenzoquat-methylsulfate, diquat or paraquat-dichloride; ureas, such as chlorbromuron, chlorotoluron, difenoxuron, dimefuron, diuron, ethidimuron, fenuron, fluometuron, isoproturon, isouron, linuron, methabenzthiazuron, methazole, metobenzuron, metoxuron, monolinuron, neburon, siduron or tebuthiuron; phenols, such as bromoxynil or ioxynil; chloridazon; triazines, such as ametryn, atrazine, cyanazine, desmein, dimethamethryn, hexazinone, prometon, prometryn, propazine, simazine, simetryn, terbumeton, terbutryn, terbutylazine or trietazine; triazinones, such as metamitron or metribuzin; uracils, such as bromacil, lenacil or terbacil; or biscarbamates, such as desmedipham or phenmedipham; C13) synergists, for example oxiranes, such as tridiphane; C14) CIS cell wall synthesis inhibitors, for example isoxaben or dichlobenil; C15) various other herbicides, for example dichloropropionic acids, such as dalapon; dihydrobenzofurans, such as ethofumesate; phenylacetic acids, such as chlorfenac (fenac); or aziprotryn, barban, bensulide, benzthiazuron, benzofluor, buminafos, buthidazole, buturon, cafenstrole, chlorbufam, chlorfenprop-methyl, chloroxuron, cinmethylin, cumyluron, cycluron, cyprazine, cyprazole, dibenzyluron, dipropetryn, dymron, eglinazin-ethyl, endothall, ethiozin, flucabazone, fluorbentranil, flupoxam, isocarbamid, isopropalin, karbutilate, mefluidide, monuron, napropamide, napropanilide, nitralin, oxaciclomefone, phenisopham, piperophos, procyazine, profluralin, pyributicarb, secbumeton, sulfallate (CDEC), terbucarb, triaziflam, triazofenamid or trimeturon; or their environmentally compatible salts.

Nematicides or bionematicides: Benomyl, cloethocarb, aldoxycarb, tirpate, diamidafos, fenamiphos, cadusafos, dichlofenthion, ethoprophos, fensulfothion, fosthiazate, heterophos, isamidofof, isazofos, phosphocarb, thionazin, imicyafos, mecarphon, acetoprole, benclothiaz, chloropicrin, dazomet, fluensulfone, 1,3-dichloropropene (telone), dimethyl disulfide, metam sodium, metam potassium, metam salt (all MITC generators), methyl bromide, biological soil amendments (e.g., mustard seeds, mustard seed extracts), steam fumigation of soil, allyl isothiocyanate (AITC), dimethyl sulfate, furfual (aldehyde).

Suitable plant growth regulators of the present invention include the following: Plant Growth Regulators: D1) Antiauxins, such as clofibric acid, 2,3,5-tri-iodobenzoic acid; D2) Auxins such as 4-CPA, 2,4-D, 2,4-DB, 2,4-DEP, dichlorprop, fenoprop, IAA, IBA, naphthaleneacetamide, α-naphthaleneacetic acids, 1-naphthol, naphthoxyacetic acids, potassium naphthenate, sodium naphthenate, 2,4,5-T; D3) cytokinins, such as 2iP, benzyladenine, 4-hydroxyphenethyl alcohol, kinetin, zeatin; D4) defoliants, such as calcium cyanamide, dimethipin, endothal, ethephon, merphos, metoxuron, pentachlorophenol, thidiazuron, tribufos; D5) ethylene inhibitors, such as aviglycine, 1-methylcyclopropene; D6) ethylene releasers, such as ACC, etacelasil, ethephon, glyoxime; D7) gametocides, such as fenridazon, maleic hydrazide; D8) gibberellins, such as gibberellins, gibberellic acid; D9) growth inhibitors, such as abscisic acid, ancymidol, butralin, carbaryl, chlorphonium, chlorpropham, dikegulac, flumetralin, fluoridamid, fosamine, glyphosine, isopyrimol, jasmonic acid, maleic hydrazide, mepiquat, piproctanyl, prohydrojasmon, propham, tiaojiean, 2,3,5-tri-iodobenzoic acid; D10) morphactins, such as chlorfluren, chlorflurenol, dichlorflurenol, flurenol; D11) growth retardants, such as chlormequat, daminozide, flurprimidol, mefluidide, paclobutrazol, tetcyclacis, uniconazole; D12) growth stimulators, such as brassinolide, brassinolide-ethyl, DCPTA, forchlorfenuron, hymexazol, prosuler, triacontanol; D13) unclassified plant growth regulators, such as bachmedesh, benzofluor, buminafos, carvone, choline chloride, ciobutide, clofencet, cyanamide, cyclanilide, cycloheximide, cyprosulfamide, epocholeone, ethychlozate, ethylene, fuphenthiourea, furalane, heptopargil, holosulf, inabenfide, karetazan, lead arsenate, methasulfocarb, prohexadione, pydanon, sintofen, triapenthenol, trinexapac.

The fertilizer can be a liquid fertilizer. The term “liquid fertilizer” refers to a fertilizer in a fluid or liquid form containing various ratios of nitrogen, phosphorous and potassium (for example, but not limited to, 10% nitrogen, 34% phosphorous and 0% potassium) and micronutrients, commonly known as starter fertilizers that are high in phosphorus and promote rapid and vigorous root growth.

Chemical formulations of the present invention can be in any appropriate conventional form, for example an emulsion concentrate (EC), a suspension concentrate (SC), a suspo-emulsion (SE), a capsule suspension (CS), a water dispersible granule (WG), an emulsifiable granule (EG), a water in oil emulsion (EO), an oil in water emulsion (EW), a micro-emulsion (ME), an oil dispersion (OD), an oil miscible flowable (OF), an oil miscible liquid (OL), a soluble concentrate (SL), an ultra-low volume suspension (SU), an ultra-low volume liquid (UL), a dispersible concentrate (DC), a wettable powder (WP) or any technically feasible formulation in combination with agriculturally acceptable adjuvants.

In one embodiment, a product is provided comprising: a first composition comprising a biologically pure culture of Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof and a biologically pure culture of Bacillus amyloliquefaciens RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof; a second composition comprising one or a combination of a microbial, a biological, or a chemical insecticide, fungicide, nematicide, bacteriocide, herbicide, plant extract, plant growth regulator, or fertilizer, wherein the first and second composition are separately packaged; and, optionally, instructions for delivering in an amount suitable to benefit plant growth, a combination of the first and second compositions to: foliage of the plant, bark of the plant, fruit of the plant, flowers of the plant, seed of the plant, roots of the plant, a cutting of the plant, a graft of the plant, callus tissue of the plant; soil or growth medium surrounding the plant; soil or growth medium before sowing seed of the plant in the soil or growth medium; or soil or growth medium before planting the plant, the plant cutting, the plant graft, or the plant callus tissue in the soil or growth medium.

In one embodiment, the first composition further comprises one or a combination of a carrier, a dispersant, or a yeast extract.

In one embodiment, the first composition is in the form of a liquid, a dust, a spreadable granule, a dry wettable powder, or a dry wettable granule. In one embodiment, the first composition is in the form of a liquid and each of the Bacillus amyloliquefaciens RTI301 and the Bacillus subtilis RTI477 is present at a concentration of from about 1.0×10⁸ CFU/ml to about 1.0×10¹² CFU/ml. In one embodiment, the first composition is in the form of a dust, a dry wettable powder, a spreadable granule, or a dry wettable granule and each of the Bacillus amyloliquefaciens RTI301 and the Bacillus subtilis RTI477 is present in an amount of from about 1.0×10⁸ CFU/g to about 1.0×10¹² CFU/g. In one embodiment, the first composition is in the form of an oil dispersion and each of the Bacillus amyloliquefaciens RTI301 and the Bacillus subtilis RTI477 is present at a concentration of from about 1.0×10⁸ CFU/ml to about 1.0×10¹² CFU/ml.

In the product, the insecticide can be one or a combination of pyrethroids, bifenthrin, tefluthrin, zeta-cypermethrin, organophosphates, chlorethoxyphos, chlorpyrifos, tebupirimphos, cyfluthrin, fiproles, fipronil, nicotinoids, or clothianidin. In one embodiment, the insecticide in the second composition of the product comprises bifenthrin. In one embodiment, the insecticide in the second composition of the product comprises bifenthrin and it is in a formulation compatible with a liquid fertilizer.

EXAMPLES

The following EXAMPLEs have been included to provide guidance to one of ordinary skill in the art for practicing representative embodiments of the presently disclosed subject matter. In light of the present invention and the general level of skill in the art, those of skill can appreciate that the following EXAMPLEs are intended to be exemplary only and that numerous changes, modifications, and alterations can be employed without departing from the scope of the presently disclosed subject matter.

Example 1 Identification of a Bacterial Isolate as a Bacillus Subtilis Through Sequence Analysis

A plant associated bacterial strain, designated herein as RTI477, was isolated from the root of Moringa oleifera grown in North Carolina. The 16S rRNA and the rpoB genes of the RTI477 strain were sequenced and subsequently compared to other known bacterial strains in the NCBI and RDP databases using BLAST. It was determined that the 16S RNA partial sequence of RTI477 (SEQ ID NO: 1) is identical to the partial 16S rRNA gene sequence of Bacillus subtilis strain BSn5 (CP002468), Bacillus amyloliquefaciens strain NS6 (KF177175), and Bacillus subtilis subsp. subtilis strain DSM 10 (NR_027552). In addition, it was determined that the rpoB sequence of RTI477 has 99% sequence identity to known strains Bacillus subtilis PY79 (CP006881), Bacillus subtilis subsp. subtilis 6051-HGW (CP003329) (i.e., 99% sequence identity; 9 bp difference), and Bacillus subtilis subsp. subtilis BAB-1a (CP004405) (i.e., 99% sequence identity; 10 bp difference). The RTI477 strain was identified as a strain of Bacillus subtilis. The differences in sequence for the rpoB gene at the DNA level indicate that RTI477 is a new strain of Bacillus subtilis. The strain of Bacillus subtilis RTI477 was deposited on 17 Apr. 2014 under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure at the American Type Culture Collection (ATCC) in Manassas, Va., USA and bears the Patent Accession No. PTA-121167.

Example 2 Identification of a Bacterial Isolate as a Bacillus Amyloliquefaciens Through Sequence Analysis

A plant associated bacterial strain, designated herein as RTI301, was isolated from the rhizosphere soil of grape vines growing at a vineyard in NY. The 16S rRNA and the rpoB genes of the RTI301 strain were sequenced and subsequently compared to other known bacterial strains in the NCBI and RDP databases using BLAST. It was determined that the 16S RNA partial sequence of RTI301 (SEQ ID NO: 3) is identical to the 16S rRNA gene sequence of Bacillus amyloliquefaciens strain NS6 (KF177175), Bacillus amyloliquefaciens strain FZB42 (NR_075005), and Bacillus subtilis subsp. subtilis strain DSM 10 (NR_027552). It was also determined that the rpoB gene sequence of RTI301 (SEQ ID NO: 4) has sequence similarity to the same gene in Bacillus amyloliquefaciens subsp. plantarum TrigoCor1448 (CP007244) (99% sequence identity; 3 base pair difference); Bacillus amyloliquefaciens subsp. plantarum AS43.3 (CP003838) (99% sequence identity; 7 base pair difference); Bacillus amyloliquefaciens CC178 (CP006845) (99% sequence identity; 8 base pair difference), and Bacillus amyloliquefaciens FZB42 (CP000560) (99% sequence identity; 8 base pair difference). The RTI301 strain was identified as a Bacillus amyloliquefaciens. The differences in sequence for the rpoB gene at the DNA level indicate that RTI301 is a new strain of Bacillus amyloliquefaciens. The strain of Bacillus amyloliquefaciens RTI301 was deposited on 17 Apr. 2014 under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure at the American Type Culture Collection (ATCC) in Manassas, Va., USA and bears the Patent Accession No. PTA-121165.

Example 3 Genes Related to Biosynthesis of Antimicrobial Compounds in Bacillus Amyloliquefaciens RTI301 and Bacillus Subtilis RTI477

Further sequence analysis of the genome of the Bacillus amyloliquefaciens RTI301 strain revealed that this strain has genes related to a number of biosynthetic pathways for production of molecules having antimicrobial properties. These include the biosynthetic pathways for subtilosin, surfactin, iturin, fengycins, amylocyclicin, difficidin, bacilysin, bacillomycin, and bacillaene. In addition, genes related to lantibiotic biosynthesis were discovered in the RTI301 strain, for which there are no homologues in the other closely related Bacillus amyloliquefaciens strains. This is illustrated in FIG. 1, which shows a schematic diagram of the genomic organization surrounding and including the lantibiotic biosynthesis operon found in Bacillus amyloliquefaciens RTI301. In FIG. 1, the top set of arrows represents protein coding regions for the RTI301 strain with relative direction of transcription indicated. For comparison, the corresponding regions for two Bacillus amyloliquefaciens reference strains, FZB42 and TrigoCor1448, are shown below the RTI301 strain. The genes in the lantibiotic synthesis operon in the RTI301 strain were initially identified using RAST and their identities then refined using BLASTp. The degree of amino acid identity of the proteins encoded by the genes of the RTI301 strain as compared to the two reference strains is indicated both by the degree of shading of the representative arrows as well as a percentage identity indicated within the arrow. It can be observed from FIG. 1 that there is a high degree of sequence identity in the genes from the 3 different strains in the regions surrounding the lantibiotic synthesis operon, but only a low degree of sequence identity within the lantibiotic synthesis operon (i.e., less than 40% within the lantibiotic synthesis operon but greater than 99% in the surrounding regions). BLASTn analysis of this cluster was performed against the non-redundant (nr)nucleotide database at NCBI and the analysis showed a high degree of homology in the 5′ and 3′ flanking regions to B. amyloliquefaciens strains (analogous to the high % similarity in FIG. 1). However, the lantipeptide biosynthetic cluster was unique to RTI301, and no significant homology to any previously sequenced DNA in the NCBI nr database was observed. Thus, this lantibiotic synthesis operon is a unique feature for Bacillus amyloliquefaciens strain RTI301.

In contrast to the RTI301 strain with its wide range of antimicrobial biosynthetic pathways, further sequence analysis of the RTI477 strain revealed that this strain has genes related to biosynthetic pathways for a more limited group of molecules having antimicrobial properties. The RTI477 strain has biosynthetic pathways for subtilosin, fengycins, surfactin, difficidin, bacillaene, bacilysin, and bacillomycin, but complete biosynthetic pathways for iturins, lantibiotics, and amylocyclicins were not observed.

Example 4 Anti-Microbial Properties of Bacillus Subtilis RTI477 and Bacillus Amyloliquefaciens RTI301 Isolates

The antagonistic ability of the Bacillus subtilis RTI477 and Bacillus amyloliquefaciens RTI301 isolates against major plant pathogens was measured in plate assays. A plate assay for evaluation of antagonism against plant fungal pathogens was performed by growing the bacterial isolate and pathogenic fungi side by side on 869 agar plates at a distance of 4 cm. Plates were incubated at room temperature and checked regularly for up to two weeks for growth behaviors such as growth inhibition, niche occupation, or no effect. In the case of screening for antagonistic properties against bacterial pathogens, the pathogen was first spread as a lawn on 869 agar plates. Subsequently, 20 μl aliquots of a culture of each of the isolates were spotted on the plate. Plates were incubated at room temperature and checked regularly for up to two weeks for an inhibition zone in the lawn around the positions were RTI477 and RTI301 had been applied. A summary of the antagonism activity is shown in Tables I and II below for each of the RTI477 and RTI301 strains, respectively. The RTI301 strain showed superior antagonistic properties against a wide range of plant pathogenic microorganisms in comparison to the RTI477 strain.

TABLE I Antagonistic properties of Bacillus subtilis RTI477 isolate against major plant pathogens Anti-Microbial Assays RTI477 Alternaria solani +++ Aspergillus flavus + Aspergillus nomius +− Botrytis cinerea ++ Cercospora sojina ++/+++ Fusarium colmorum + Fusarium graminearum +++ Fusarium oxysporum f. sp. Lycopersici + Fusarium oxysporum f. sp. cubense + Fusarium virguliforme ++/+++ Glomerella cingulata ++ Magnaporthe grisea +++ Monilina fructicola ++ Rhizoctonia solani ++ Sclerotinia homeocarpa ++ Sclerotinia sclerotiorum + Septoria tritici ++ Stagonospora nodorum ++/+++ Phytophthora capsici ++ Pythium sylvatium +−/+ Pythium aphanidermatum + Erwinia amylovora + Erwinia carotovora + Pseudomonas syringae pv. tomato − Xanthomonas axonopodis + Xanthomonas euvesicatoria + +++ very strong activity, ++ strong activity, + activity, +− weak activity, − no activity observed

TABLE II Antagonistic properties of Bacillus amyloliquefaciens RTI301 isolate against major plant pathogens. Anti-Microbial Assays RTI301 Alternaria solani ++ Aspergillus flavus ++ Aspergillus nomius +++ Botrytis cinerea +++ Cercospora sojina +++ Fusarium colmorum + Fusarium graminearum +++ Fusarium oxysporum f. sp. Lycopersici ++ Fusarium oxysporum f. sp. cubense ++ Fusarium virguliforme ++/+++ Glomerella cingulata +++ Magnaporthe grisea ++/+++ Monilina fructicola ++/+++ Rhizoctonia solani ++ Sclerotinia homeocarpa ++/+++ Sclerotinia sclerotiorum +++ Septoria tritici ++ Stagonospora nodorum ++/+++ Phytophthora capsici ++ Pythium sylvatium +−/+ Pythium aphanidermatum + Erwinia amylovora + Erwinia carotovora + Pseudomonas syringae pv. tomato − Ralstonia solenacearum ++ Xanthomonas axonopodis ++ Xanthomonas euvesicatoria ++ +++ very strong activity, ++ strong activity, + activity, +− weak activity, − no activity observed

Example 5 Phenotypic Traits of Bacillus Subtilis RTI477 and Bacillus Amyloliquefaciens RTI301 Isolates

In addition to the antagonistic properties, various phenotypic traits were also measured for the Bacillus subtilis RTI477 and Bacillus amyloliquefaciens RTI301 strains and the data are shown below in Tables III and IV for each of the strains respectively. The assays were performed according to the procedures described in the text below the Tables. Notably, RTI477 grows faster and has a strong swarming phenotype as compared to RTI301.

TABLE III Phenotypic Assays: phytohormone production, acetoin and indole acetic acid (IAA), and nutrient cycling of Bacillus subtilis RTI477 isolate. Characteristic Assays RTI477 Acid Production (Methyl Red) − Acetoin production (MR-VP) ++ Chitinase activity − Indole-3-Acetic Acid production − Protease activity ++ Phosphate solubilization +− Phenotype dry cream, large growth, strong swarming +++ very strong, ++ strong, + some, +− weak, − none observed

TABLE IV Phenotypic Assays: phytohormone production, acetoin and indole acetic acid (IAA), and nutrient Cycling of Bacillus amyloliquefaciens RTI301 isolate. Characteristic Assays RTI301 Acid Production (Methyl Red) − Acetoin Production (MR-VP) +++ Chitinase activity +− lndole-3-Acetic Acid production − Protease activity +++ Phosphate Solubilization +− Phenotype slimy cream, well- defined, round colonies +++ very strong, ++ strong, + some, +− weak, − none observed

Acetoin Test.

20 μl of a starter culture in rich 869 media was transferred to 1 ml Methy Red—Voges Proskauer media (Sigma Aldrich 39484). Cultures were incubated for 2 days at 30 C 200 rpm. 0.5 ml culture was transferred and 50 μl 0.2 g/l methyl red was added. Red color indicated acid production. The remaining 0.5 ml culture was mixed with 0.3 ml 5% alpha-napthol (Sigma Aldrich N1000) followed by 0.1 ml 40% KOH. Samples were interpreted after 30 minutes of incubation. Development of a red color indicated acetoin production. For both acid and acetoin tests non-inoculated media was used as a negative control (Sokol et al., 1979, Journal of Clinical Microbiology. 9: 538-540).

Indole-3-Acetic Acid.

20 μl of a starter culture in rich 869 media was transferred to 1 ml 1/10 869 Media supplemented with 0.5 g/l tryptophan (Sigma Aldrich T0254). Cultures were incubated for 4-5 days in the dark at 30 C, 200 RPM. Samples were centrifuged and 0.1 ml supernatant was mixed with 0.2 ml Salkowski's Reagent (35% perchloric acid, 10 mM FeCl3). After incubating for 30 minutes in the dark, samples resulting in pink color were recorded positive for IAA synthesis. Dilutions of IAA (Sigma Aldrich I5148) were used as a positive comparison; non inoculated media was used as negative control (Taghavi, et al., 2009, Applied and Environmental Microbiology 75: 748-757).

Phosphate Solubilizing Test.

Bacteria were plated on Pikovskaya (PVK) agar medium consisting of 10 g glucose, 5 g calcium triphosphate, 0.2 g potassium chloride, 0.5 g ammonium sulfate, 0.2 g sodium chloride, 0.1 g magnesium sulfate heptahydrate, 0.5 g yeast extract, 2 mg manganese sulfate, 2 mg iron sulfate and 15 g agar per liter, pH7, autoclaved. Zones of clearing were indicative of phosphate solubilizing bacteria (Sharma et al., 2011, Journal of Microbiology and Biotechnology Research 1: 90-95).

Chitinase Activity.

10% wet weight colloidal chitin was added to modified PVK agar medium (10 g glucose, 0.2 g potassium chloride, 0.5 g ammonium sulfate, 0.2 g sodium chloride, 0.1 g magnesium sulfate heptahydrate, 0.5 g yeast extract, 2 mg manganese sulfate, 2 mg iron sulfate and 15 g agar per liter, pH7, autoclaved). Bacteria were plated on these chitin plates; zones of clearing indicated chitinase activity (N. K. S. Murthy & Bleakley, 2012. “Simplified Method of Preparing Colloidal Chitin Used for Screening of Chitinase Producing Microorganisms”. The Internet Journal of Microbiology. 10(2)).

Protease Activity.

Bacteria were plated on 869 agar medium supplemented with 10% milk. Clearing zones indicated the ability to break down proteins suggesting protease activity (Sokol et al., 1979, Journal of Clinical Microbiology. 9: 538-540).

Example 6 Growth Effects of Bacillus Subtilis RTI477 Isolate in Wheat

The effect of application of the bacterial isolate RTI477 on early plant growth and vigor in wheat was determined. The experiment was performed by inoculating surface sterilized germinated wheat seeds for 2 days in a suspension of ^(˜)2×10⁷ CFU/ml of the bacterium at room temperature under aeration in the dark (a control was also performed without bacteria). Subsequently, the inoculated and control seeds were planted in 6″ pots filled with sand. 10 seeds per pot and 1 pot per treatment were planted and watered as needed alternating with water and Modified Hoagland's solution. Pots were incubated in a lab windowsill at approximately 21° C. providing natural light/dark cycles for 13 days at which point plants were recovered and parameters measured. Dry weight was determined as a total weight per 9 plants resulting in a total average dry plant weight equal to 35.41 mg for the plants inoculated with the Bacillus subtilis RTI477 strain versus a weight equal to 33.38 mg for the non-inoculated control which is a 6% increase in dry weight over the non-inoculated control. Photographs of the extracted plants after 13 days growth are shown in FIG. 2. FIG. 2A shows control plants and FIG. 2B shows plants inoculated with RTI477.

Example 7 Growth Compatibility of Bacillus Amyloliquefaciens RTI301 and Bacillus Subtilis RTI477

The compatibility of the strain Bacillus amyloliquefaciens RTI301 with other Bacillus isolates was tested by spotting the RTI301 strain onto a lawn of the various other strains. Results of this experiment are shown in FIGS. 3A-3B. FIGS. 3A-3B are images showing the growth compatibility between strains Bacillus amyloliquefaciens RTI301 and Bacillus subtilis RTI477 and a lack of compatibility between the RTI301 strain with another Bacillus amyloliquefaciens strain, Bacillus amyloliquefaciens RTI472 deposited as PTA-121166 with the American Type Culture Collection (ATCC). When strain RTI301 was spotted onto a lawn of strain RTI472 (FIG. 3A), a clear inhibition zone was observed for the growth of strain RTI472. In contrast, when strain RTI301 was spotted onto a lawn of strain RTI477 (FIG. 3B), only minimal inhibition and no clearing of the cell lawn was observed for the RTI477 strain. Therefore, it was concluded that the growth of RTI301 and RTI477 is compatible.

Without being limited to any particular mechanism of action, one mode of action is proposed as follows to explain the observed differences in strain compatibility. Based on the genome sequences of the three strains tested (i.e., RTI301, RTI472, and RTI477), these strains were all predicted to produce the antagonistic compounds bacilysin, bacillaene, difficidin, and bacillomycin. However, while both Bacillus amyloliquefaciens RTI301 and Bacillus subtilis RTI477 possess the gene for synthesis of subtilosin, this gene is absent in the genome of Bacillus amyloliquefaciens RTI472. Subtilosin is a bacteriocin, a class of proteinaceous toxins produced by bacteria to inhibit the growth of similar or closely related bacterial strain(s). Therefore, it was postulated that the subtilosin synthesized by Bacillus amyloliquefaciens RTI301 could be the inhibitor of the growth of Bacillus amyloliquefaciens RTI472. In contrast, the Bacillus subtilis RTI477 strain is not inhibited by RTI301, because the RTI477 strain produces its own subtilosin and is thus resistant to the compound.

The differences in strain morphology between the Bacillus amyloliquefaciens RTI301 and Bacillus subtilis RTI477 strains were also analyzed. Images showing the morphology of each of these strains are shown in FIG. 4: Bacillus amyloliquefaciens RTI301 (FIG. 4A) and Bacillus subtilis RTI477 (FIG. 4B). The colony morphology of the Bacillus amyloliquefaciens RTI301 and Bacillus subtilis RTI477 strains shown in FIGS. 4A-4B indicate a potential difference in strain behavior when it comes to motility. Motility is a key trait for rhizosphere colonization by plant associated bacteria. Bacillus amyloliquefaciens RTI301 grows as well-defined, round colonies. In contrast, Bacillus subtilis RTI477 grows as a fluffy colony, a morphology which is indicative of swarming and motility. Swarming and motility are potentially important phenotypes for the rapid colonization of the rhizosphere and the surface of the plant root. Again, without being limited to any particular mechanism of action, it was postulated that the strong swarming phenotype suggested by the morphology of the Bacillus subtilis RTI477 strain, could cause this strain to be a more efficient colonizer of the rhizosphere than Bacillus amyloliquefaciens RTI301.

In light of the growth compatibility and observed differences in phenotype, the combination of the RTI301 and RTI477 strains was further tested for activity in promoting plant growth and health.

Example 8 Combination of Bacillus Subtilis RTI477 and Bacillus Amyloliquefaciens RTI301 Results in Synergistic Plant Growth Promoting Properties

A positive effect on seed germination and root development and architecture was observed for a variety of plant seeds inoculated with vegetative cells or coated with spores of the Bacillus subtilis RTI477 strain. This is described in wheat, for example, herein above at EXAMPLE 6. In addition, experiments were performed to determine the effects of application of Bacillus subtilis RTI477 and Bacillus amyloliquefaciens RTI301 strains to soybean seed on germination, root development and architecture, and early plant growth and/or plant health. Experiments were performed as described below using spores of RTI301 and RTI477. For the experiments, the strains were sporulated in 2×SG in a 14 L fermenter. Spores were collected but not washed afterwards at a concentration of 1.0×10⁸ CFU/mL. The spore concentration was diluted down by a factor of 10 or greater in the experiments. A sterile filter paper was placed in the bottom of individual sterile plastic growth chambers, and six seeds were placed in each container. Three mL of each dilution of the RTI301 or RTI477 spores was added to the growth chambers, which were closed and incubated at 19° C. for 8 days, after which the seedlings were imaged. In addition, combinations of RTI301 and RTI477 spores added in ratios of 1:3, 1:1 and 3:1 were also tested. Data are shown in Table V below. Neither of the two strains when applied alone inhibited seed germination as compared to non-inoculated controls.

Inoculation of soybean seeds with Bacillus amyloliquefaciens RTI301 at concentrations of 1×10⁶, 1×10⁷, and 1×10⁸ had no effect on root development and architecture. Inoculation of soybean seeds with Bacillus subtilis RTI477 at the same concentrations provided only a slight improvement at the lowest concentration on root development and architecture. Unexpectedly, inoculation of soybean seeds with the combination of both RTI301 and RTI477 (ratio 1:3) resulted at all concentrations tested in an improvement in root development. Inoculation of soybean seeds with the combination of RTI301 and RTI477 (ratio 1:1) resulted for the concentrations of 1×10⁶ CFU/ml and 1×10⁷ CFU/ml in an improvement in root development, with the most consistent results observed for the concentration of 1×10⁶ CFU/ml. The best results on root development were observed when RTI301 and RTI477 were applied in a ratio of 3:1 at the concentration of 1×10⁶ CFU/ml.

In addition, images of the positive effects of inoculation of the seed with the RTI301 plus RTI477 spores (ratio 3:1) are shown in FIGS. 5A and 5B (A—Control plants; B—plants inoculated with RTI301 plus RTI477 (ratio 3:1) at 10⁶ cfu/ml). The effects were especially positive with regards to root formation and architecture, as shown in FIGS. 5A-5B. Fine root hairs are important in the uptake of water, nutrients and plant interaction with other microorganisms in the rhizosphere. These results show that while the application of individual strains had no or little effect compared to control plants, seed treatment with application of a combination of Bacillus subtilis RTI477 and Bacillus amyloliquefaciens RTI301 strains can have significant benefit on soybean early growth and establishment.

TABLE V Soybean seed germination assay for treatment with spores of RTI301 and RTI477 Effect of spore concentration (CFU/ml) on soybean germination and root development Strain ID 10⁸ 10⁷ 10⁶ RTI 301 B. amyloliquifaciens = = = RTI 477 B. subtilis = = + RTI301 + B. amyloliquifaciens + + ++ + RTI477 B. subtilis 1:3 RTI301 + B. amyloliquifaciens + = + ++ RTI477 B. subtilis 1:1 RTI301 + B. amyloliquifaciens + = = +++ RTI477 B. subtilis 3:1 +++ very pronounced growth benefit, ++ strong growth benefit, + growth benefit, +− weak growth benefit, = no effect observed, − weak inhibition, −− strong inhibition, n.d. not determined

Additional experiments were performed to investigate the effect on plant growth and development after inoculation of the plant seed with a combination of the RTI301 and RTI477 strains. Specifically, an experiment in soybean was set up as follows: 1) seed was untreated; 2) seed was treated with a combination of CRUISERMAXX (insecticide plus fungicide, containing thiamethoxam, fludioxonil plus metalaxyl-M; SYNGENTA CROP PROTECTION, INC) and the thiophanate methyl fungicide, which is a typical soybean seed treatment (the combination of CRUISERMAXX and thiophanate methyl is referred to as “CHEM CONTROL”); 3) seed was treated with CHEM CONTROL plus inoculated with 5.0×10⁺⁵ cfu/seed of strain RTI301; 4) seed was treated with CHEM CONTROL plus inoculated with 5.0×10⁺⁵ cfu/seed of strain RTI477; 5) seed was treated with CHEM CONTROL plus inoculated with a combination of both strains at 5.0×10⁺⁵ cfu/seed. Ten trials were performed with 4 or 5 replicates per treatment per trial. The average soybean yield results (bushels per acre) for ten field trials are presented in Table VI below, with trial field sites being located in Wisconsin(2), Indiana (2), Illinois (3) and Iowa (3). Four trials were inoculated with Rhizoctonia solani, three trials were inoculated with either Fusarium graminearum or F. virguliforme, one trial was inoculated with Phytophthora sojae and two trials were non-inoculated. Each pathogen was grown separately on moisten autoclaved grain seed and then air dried. The dried inoculum used in a selected trial was planted mixed with the seed at a prescribed rate to provide infection when the seed commenced to grow.

The results in Table VI show that inoculation with either Bacillus amyloliquefaciens RTI301 or Bacillus subtilis RTI477 alone had no effect on the overall average yield of soybean when compared to seeds that were treated with the CHEM CONTROL alone. As was observed in the previous experiment, inoculating with the combination of the Bacillus amyloliquefaciens RTI301 and Bacillus subtilis RTI477 provided a synergistic effect and resulted on average over 10 field trials in a 5% increase in soybean yield (from 58.2 to 61.1 bushels per acre, see Table VI). Notably, a yield benefit of 3.7 bushels per acre was observed with the combination of RTI 301 and RTI 477 plus chemical control over the chemical control for yields in non-inoculated field trials (N=2 trials), 4.3 bushels per acre increase for the two strains plus chemical control over the chemical control for trials inoculated with Rhizoctonia (N=4 trials), 1.5 bushels per acre increase for the two strains plus chemical control over the chemical control for trials inoculated with Fusarium (N=3 trials), and 1.0 bushels per acre increase for the two strains plus chemical control over the chemical control for trials inoculated with Phytophthora (N=1 trial), so a yield response occurred irrespective of disease inoculation and seed treatment with chemical fungicides.

TABLE VI Average results of inoculation of soybean seed with Bacillus amyloliquefaciens RTI301, Bacillus subtilis RTI477 and the combination of both strains. Yield Yield Increase Paired (Bu/Acre) Over CHEM T-test TREATMENT n = 10 CONTROL Value 1 UNTREATED SEED 55.6 −2.6 0.011 2 CHEM CONTROL 58.2 ~ ~ 3 CHEM CONTROL + RTI301 58.1 −0.1 0.468 4 CHEM CONTROL + RTI477 58.1 −0.1 0.460 5 CHEM CONTROL + 61.1  2.9 0.007 RTI301 + RTI477

Without being limited to any particular mechanism of action, one explanation for the observed synergistic results of the combination of the two strains on soybean yield is as follows. Bacillus amyloliquefaciens RTI301 produces a wide range of antagonistic metabolites, such as subtilosin, that can inhibit the growth and development of competing strains both fungi and bacteria, including closely related Bacillus species. By doing so, the RTI301 strain when applied to a plant alone could open a niche/space for its establishment in the rhizosphere. However, data do not support strong plant growth promoting properties for Bacillus amyloliquefaciens RTI301. Thus, after the RTI301 strain has been introduced and has opened a niche in the rhizosphere, it could become established but fail to significantly promote plant growth and/or plant health. This is confirmed by the lack of an observed yield increase for soybean after seed treatment with Bacillus amyloliquefaciens RTI301 alone.

In contrast, Bacillus subtilis RTI477 appears to have a narrower range of antagonism than Bacillus amyloliquefaciens RTI301 and, thus, could be expected to be less efficient in opening a niche in which to become established when it is applied to plant seed alone. As a result, the strain could more easily fail to become established in the rhizosphere of soybean which could result in a lack of a beneficial effect on plant growth. This is confirmed by the observed lack of an increase in yield for soybean after seed treatment with Bacillus subtilis RTI477 alone.

Experiments have shown that the growth of the Bacillus subtilis RTI477 strain is compatible with Bacillus amyloliquefaciens RTI301. In addition, the phenotype of RTI477 indicates that this strain can be a strong swarming phenotype and it is thus hypothesized to be a more efficient colonizer of the rhizosphere than Bacillus amyloliquefaciens RTI301. Therefore, the combination of both strains can be expected to have a beneficial effect on soybean. Specifically, once Bacillus amyloliquefaciens RTI301 has opened a niche for establishment in the soybean rhizosphere, the strain can be outcompeted by Bacillus subtilis RTI477 due to its swarming phenotype. The RTI477 strain can then establish itself in the rhozosphere of soybean, where it can provide beneficial effects to its plant host. This was confirmed by the observed increase in yield of soybean after inoculation of the plant seed with a combination of both of the strains.

Example 9 Seed Treatment with a Combination of Bacillus Subtilis RTI477 and Bacillus Amyloliquefaciens RTI301 Spores Increased Yield in Corn

Additional experiments were performed to investigate the effect on plant growth, development, and yield after inoculation of the plant seed with a combination of the RTI301 and RTI477 strains.

Specifically, an experiment in corn was set up as follows and the data are summarized in Table IX below: 1) seed was untreated (“UTC”); 2) seed was treated with a combination of MAXIM (broad-spectrum seed treatment fungicide fludioxonil as its active ingredient at 0.0625 mg/seed; SYNGENTA CROP PROTECTION, INC), APRON XL (active ingredient metalaxyl-M at 0.0625 mg/seed); SYNGENTA CROP PROTECTION, INC) and PONCHO (Clothianidin insecticide at 0.25 mg/seed; BAYER CROPSCIENCE, INC), which is a typical corn seed treatment (the combination of MAXIM, APRON XL and PONCHO is referred to as “CHEM CONTROL” or “CC”); and 3) seed was treated with CHEM CONTROL plus a combination of 5.0×10⁺⁵ cfu/seed of each of strains RTI301 and RTI477 (“CC+RTI 301/477 1:1”). Two trials were performed with 5 replicates per treatment per trial, under conditions of natural disease pressure or inoculation of the soil with Rhizoctonia, respectively. For the inoculation trial, Rhizoctonia was grown separately on moistened autoclaved grain seed and then air dried. The dried inoculum was mixed with the seed at planting at a prescribed rate to provide infection when the seed commenced to grow. The average corn yield results (bushels per acre) for the field trials are presented in Table IX below, with trial field sites being located in Shawneetown, Ill.

The results in Table VII show that inoculation with the CHEM CONTROL plus the 1 to 1 combination of Bacillus amyloliquefaciens RTI301 and Bacillus subtilis RTI477 significantly increased the average corn yield when compared to seeds that were treated with the CHEM CONTROL alone. Notably, a yield increase of 10.7 bushels per acre and 59.8 bushels per acre was observed with the 1:1 combination of RTI301 and RTI477 plus chemical control over the chemical control alone for the natural pathogen pressure and the Rhizoctonia inoculated field trials, respectively. These data indicate that treatment of seed with the combination of these strains significantly enhances corn yield.

TABLE VII Yield increase for untreated corn seed (UTC), corn seed treated with chemical control (CC), and corn seed treated with CC plus a combination of Bacillus amyloliquefaciens RTI301 and Bacillus subtilis RTI477 under both natural disease pressure and artificial inoculation with Rhizoctonia. The statistical relevance (as letters) is based on P = 0.1. Natural Rhizoctonia Bu/Acre Increase Bu/Acre Increase 1 UTC 170.7 e −23.8 142 e −22.0 2 CC 194.5 bcd 0.0 164 de 0.0 3 CC + RTI 301/477 205.2 a-d 10.7 223.8 ab 59.8 1:1

Example 10 Seed Treatment with a Combination of Bacillus Subtilis RTI477 and Bacillus Amyloliquefaciens RTI301 Increased Yield in Soybean Artificially Inoculated with Rhizoctonia solani

Experiments were performed to investigate the effect on emergence and yield in soybean when seeds were treated with a combination of the RTI301 and RTI477 strains in addition to chemical active agents for pathogen control. Specifically, an experiment in soybean was set up as follows: 1) seed was untreated (UTC); 2) seed was treated with a combination of CRUISERMAXX (insecticide plus fungicide, containing thiamethoxam, fludioxonil plus metalaxyl-M; SYNGENTA CROP PROTECTION, INC) and the thiophanate methyl fungicide, which is a typical soybean seed treatment (the combination of CRUISERMAXX and thiophanate methyl is referred to as “CHEM CONTROL”); 3) seed was treated with VIBRANCE (active ingredient Sedaxane; SYNGENTA CROP PROTECTION, INC; and 4) seed was treated with CHEM CONTROL plus 5.0×10⁺⁵ cfu/seed of each of strain RTI301 and RTI477. Two trials were performed in Whitewater, Wis. with 4 replicates per treatment per trial. The trials were inoculated with Rhizoctonia solani by first growing the pathogen separately on moistened autoclaved grain seed and subsequently the dried inoculum was mixed with the seed at the time of planting to a prescribed rate to provide infection when the seed commenced to grow. The average soybean emergence and yield results for the trials are presented in Table VIII below. The results in Table VIII show that treating with the combination of the Bacillus amyloliquefaciens RTI301 and Bacillus subtilis RTI477 in addition to the CHEM CONTROL resulted in an average increase in yield of 13.3 bushels per acre over that of the chemical active agent alone (from 59.4 to 72.7 bushels per acre). Thus, seed treatment with the combination of RTI301 and RTI477 can provide significant improvement in yields in soybean, even under conditions of severe pathogen pressure.

TABLE VIII Average results on soybean emergence and yield in field trials with plants artificially inoculated with Rhizoctonia solani with treatment of the soybean seed with a combination of B. amyloliquefaciens RTI301 and B. subtilis RTI477 in addition to chemical active agent treatment for soybean seeds. Yield Increase Over CHEM % Yield CONTROL TREATMENT Emergence (Bu/Acre) (Bu/Acre) 1 UTC 36 49.3 −10.1 2 CHEM CONTROL 49 59.4 — 3 VIBRANCE 56 60.8 1.4 4 CHEM CONTROL + 65 72.7 13.3 RTI301 + RTI477

Example 11 Effects of Drip Irrigation with Bacillus amyloliquefaciens Isolate RTI301 Plus Bacillus subtilis Isolate RTI477 on Fruit and Vegetables

Field trial experiments were performed to determine the effect of drip irrigation with spores of Bacillus amyloliquefaciens RTI301 plus Bacillus subtilis RTI477 on squash, tomato and pepper. Disease pressure caused by soil-borne fungi was not recorded for any of the trails. The effects on plant yield were determined according to the experiments described below.

A field trial was performed for pepper plants (jalapeno pepper) where spores were applied at a rate of 1.25×10¹² CFU/hectare per strain of both Bacillus amyloliquefaciens RTI301 and Bacillus subtilis RTI477 at the time of planting via a root-zone drench, followed by two drip applications of the same rate at 17 and 35 days after transplanting. ACCOMPLISH LM (LOVELAND PRODUCTS) was used as the commercial control and was applied in the same manner as described for the RTI301+RTI477 combination at a rate of 2340 ml/Ha. This product contains a blend of Acidovorax facilis (1×10³ cfu/ml), Bacillus licheniformis (1×10³ cfu/ml), Bacillus subtilis (1×10³ cfu/ml), Bacillus oleronius (1×10³ cfu/ml), Bacillus marinus (1×10³ cfu/ml), Bacillus megaterium (1×10³ cfu/ml), and Rhodococcus rhodochrous(1×10³ cfu/ml).

The addition of the RTI301 plus RTI477 spores resulted in an increase in yield for jalapeno peppers as compared to untreated control plants in which bacterial spores were not applied, as well as in comparison to the commercial control plants. Specifically, RTI301+RTI477 treated plants resulted in a total of 4154 kg/Ha marketable peppers, as compared to 3455 kg/Ha and 3930 kg/Ha for the untreated control plants and the plants treated with ACCOMPLISH, respectively, representing a 20% and a 5.7% respective increase in weight of marketable peppers. The substantial increase in marketable pepper weight of the plants treated with Bacillus amyloliquefaciens RTI301 plus Bacillus subtilis RTI477 spores relative to the untreated control plants and the plants treated with the commercial standard demonstrates the positive growth effect provided by this treatment.

A similar field trial was performed for tomato plants where spores were applied at a rate of 0.625×10¹² CFU/hectare for Bacillus amyloliquefaciens RTI301 and at a rate of 3.75×10¹² CFU/hectare for Bacillus subtilis RTI477 at the time of planting via a root-zone drench, followed by two drip applications of the same rate at 17 and 35 days after transplanting. ACCOMPLISH LM was used as the commercial control and applied in the same manner as described for the RTI301+RTI477 combination at a rate of 2340 ml/Ha.

The addition of the RTI301 plus RTI477 spores resulted in an increase in both total and marketable yield for tomatoes compared to untreated control plants in which bacterial spores were not included in the drench and the irrigation, as well as in comparison to the commercial control plants. Specifically, RTI301+RTI477 treated plants resulted in a total of 21,824 kg/Ha marketable tomatoes, as compared to 16,765 kg/Ha and 21,420 kg/Ha for the untreated control plants and the plants treated with ACCOMPLISH, respectively, representing a 30.2% and 1.9% respective increase in weight of marketable tomatoes. The substantial increase in marketable tomato weight of the plants treated with Bacillus amyloliquefaciens RTI301 plus Bacillus subtilis RTI477 spores, especially compared to the untreated control plants, demonstrates the positive growth effect provided by this treatment.

A similar field trial was performed for squash plants where spores were applied at a rate of 3.75×10¹² CFU/hectare for Bacillus amyloliquefaciens RTI301 and at a rate of 0.625×10¹² CFU/hectare for Bacillus subtilis RTI477 at the time of planting via a root-zone drench, without further application via drip irrigation. ACCOMPLISH LM was used as the commercial control and applied in the same manner as described for the RTI301+RTI477 combination at a rate of 2340 ml/Ha.

The addition of the RTI301 plus RTI477 spores resulted in an increase in both total and marketable yield for squash compared to untreated control plants in which bacterial spores were not included in the drench, as well as in comparison to the commercial control plants. Specifically, RTI301+RTI477 treated plants resulted in a total of 873.4 kg/Ha squash, as compared to 838.3 kg/Ha and 836.1 kg/Ha for the untreated control plants and the plants treated with ACCOMPLISH, respectively, representing a 4.2% and 4.5% respective increase in weight of total squash. The increase in total squash weight of the plants treated with Bacillus amyloliquefaciens RTI301 plus Bacillus subtilis RTI477 spores relative to the untreated control plants and the plants treated with the commercial standard demonstrates the positive growth effect provided by this treatment.

Example 12 Identification of New Metabolites Produced by Bacillus Subtilis RTI477 and Bacillus Amyloliquefaciens RTI301 Isolates

It has been previously reported that five classes of Fengycin-type metabolites and Dehydroxyfengycin-type metabolites are produced by microbial species including Bacillus subtilis and Bacillus amyloliquefaciens (see, for example, Li, Xing-Yu, et al., 2013, J. Microbiol. Biotechnol. 23(3), 313-321; Pecci Y, et al. 2010, Mass Spectrom., 45(7):772-77). These metabolites are cyclic peptide molecules that also contain a fatty acid group. The five classes of Fengycin- and Dehydroxyfengycin-type metabolites are referred to as A, B, C, D and S. The backbone structure of these metabolites as well as the specific amino acid sequence for each of the five classes is shown in FIG. 6. In Bacillus subtilis the Fengycin-type compounds are referred to as Plipastatins. Plipastatin A and B are similar in molecular weight to Fengycin A and B, and only differ in the aspect that the Tyrosine residue at position 3 of the peptide ring is the D-form in the Fengycins and the L-form in the Plipastatins, and the Tyrosine residue at position 9 of the peptide ring is the L-form in the Fengycins and the D-form in the Plipastatins. (Marc Ongena and Philippe Jacques, 2007, Trends in Microbiology Vol. 16, No. 3: 115-125). For the purposes of this specification and claims, the term “Fengycin” will be used to refer to both Plipastatin metabolites and Fengycin metabolites. Similarly, for the purposes of this specification and claims, the term “Dehydroxyfengycin” will be used to refer to both Dehydroxyplipastatin metabolites and Dehydroxyfengycin metabolites.

The Fengycin- and Dehydroxyfengycin-type metabolites produced by Bacillus subtilis RTI477 and Bacillus amyloliquefaciens RTI301 were analyzed using UHPLC-TOF MS. The molecular weights of the these metabolites produced by the strains after 6 days growth in 869 medium or 2×SG medium at 30° C. were compared to the theoretical molecular weights expected for the Fengycin- and Dehydroxyfengycin-type metabolites. In addition, to determine the amino acid composition of the various Fengycin-type metabolites produced by the strains, peptide sequencing using LC-MS-MS was performed on each of the Fengycin-type metabolites previously identified via UHPLC-TOF MS. In this manner, it was determined that the strains produce Fengycin A, B, C, D, and S and Dehydroxyfengycin A, B, C, D, and S. Surprisingly, in addition to these known compounds, it was determined that the strains also produce previously unidentified derivatives of these compounds.

For example, it was determined that the Bacillus amyloliquefaciens RTI301 strain produces Fengycin-like and Dehydroxyfengycin-like compounds where the L-isoleucine at position 8 of the cyclic peptide chain (referred to as X₃ in FIG. 6) is replaced by L-methionine. The new classes of Fengycin and Dehydroxyfengycin are referred to herein as MA, MB and MC, referring to derivatives of classes A, B and C in which the L-isoleucine at X₃ in FIG. 6 has been replaced by L-methionine. The newly identified molecules are shown in FIG. 6 and in Table IX below. The newly identified Fengycin MA, MB and MC compounds were also observed for the RTI477 strain, however the corresponding Dehydroxyfengycin MA, MB and MC compounds were not observed for the RTI477 strain (Table IX).

It was further determined that the RTI301 strain produces an additional class of Fengycin and Dehydroxyfengycin that has not been previously identified. In this class, the L-isoleucine of Fengycin B and Dehydroxyfengycin B (position X₃ in FIG. 6) is replaced by L-homo-cysteine (Hcy). These previously unidentified Fengycin and Dehydroxyfengycin metabolites are referred to herein as Fengycin H and Dehydroxyfengycin H and are shown in FIG. 6 and Table IX. The newly identified Fengycin H compound was also observed for the RTI477 strain, however the corresponding Dehydroxyfengycin H compound was not observed for the RTI477 strain (Table IX).

It was further determined that the RTI301 strain produces an additional class of previously unidentified Fengycin and Dehydroxyfengycin metabolites. In this class, the amino acid at position 4 of the cyclic peptide backbone structure (position X₁ in FIG. 6) is replaced by L-isoleucine. These previously unidentified metabolites are referred to herein as Fengicin I and Dehydroxyfengicin I and are shown in FIG. 6 and in Table IX. Both the newly identified Fengycin I and Dehydroxyfengycin I compounds were also observed for the RTI477 strain (Table IX).

A summary of the amino acid sequences for the previously reported Fengycin- and Dehydroxyfengycin-type metabolites and the newly identified metabolites is provided in Table IX below.

TABLE IX Summary of MS/MS identification of Fengycin-type metabolites in Bacillus subtilis RTI477 and Bacillus amyloliquefaciens RTI301 isolates. Theoretical C16 Theoretical Ring Molecular C16 Observed Observed Homolog X₁ X₂ X₃ R Mass Formula [M + H]⁺ RTI301 RTI477 Fengycin A Ala Thr Ile OH 1080.6 C₇₂H₁₁₀N₁₂O₂₀ 1463.8 C15, C16, C17 C14, C15, C16, C17 Fengycin B Val Thr Ile OH 1108.7 C₇₄H₁₁₄N₁₂O₂₀ 1491.8 C14, C15, C14, C15, C16, C17 C16, C17 Fengycin C Aba Thr Ile OH 1094.6 C₇₃H₁₁₂N₁₂O₂₀ 1477.8 C14, C15, C14, C15, C16, C17 C16, C17 Fengycin D Val Thr Val OH 1094.6 C₇₃H₁₁₂N₁₂O₂₀ 1477.8 C14, C15, C14, C15, C16, C17 C16, C17 Fengycin S Val Ser Ile OH 1094.6 C₇₃H₁₁₂N₁₂O₂₀ 1477.8 C14, C15, C14, C15, C16, C17 C16, C17 Fengycin MA Ala Thr Met OH 1098.7 C₇₁H₁₀₈N₁₁₂O₂₀S 1481.8 C15, C16, C17 C15, C16, C17 Fengycin MB Val Thr Met OH 1126.8 C₇₃H₁₁₂N₁₂O₂₀S 1509.8 C14, C15, C16 C14, C15, C16, C17 Fengycin MC Aba Thr Met OH 1112.7 C₇₂H₁₁₀N₁₁₂O₂₀S 1495.8 C14, C15, C14, C15, C16, C17 C16, C17 Fengycin H Val Thr Hcy OH 1112.7 C₇₂H₁₁₀N₁₁₂O₂₀S 1495.8 C14, C15, C14, C15, C16, C17 C16, C17 Fengycin I Ile Thr Ile OH 1122.8 C₇₅H₁₁₆N₁₂O₂₀ 1505.8 C16, C17 C16 Dehydroxyfengycin Ala Thr Ile H 1080.6 C₇₂H₁₁₀N₁₁₂O₁₉ 1447.8 C15, C16, C17 C14, C15, A C16, C17 Dehydroxyfengycin Val Thr Ile H 1108.7 C₇₄H₁₁₄N₁₂O₁₉ 1475.8 C14, C15, C14, C15, B C16, C17 C16, C17 Dehydroxyfengycin Aba Thr Ile H 1094.6 C₇₃H₁₁₂N₁₂O₁₉ 1461.8 C14, C15, C14, C15, C C16, C17 C16, C17 Dehydroxyfengycin Val Thr Val H 1094.6 C₇₃H₁₁₂N₁₂O₁₉ 1461.8 C14, C15, C14, C15, D C16, C17 C16, C17 Dehydroxyfengycin Val Ser Ile H 1094.6 C₇₃H₁₁₂N₁₂O₁₉ 1461.8 C14, C15, C14, C15, S C16, C17 C16, C17 Dehydroxyfengycin Ala Thr Met H 1098.7 C₇₁H₁₀₈N₁₁₂O₁₉S 1465.7 C14 Not observed MA Dehydroxyfengycin Val Thr Met H 1126.8 C₇₃H₁₁₂N₁₂O₁₉S 1493.8 C15 Not observed MB Dehydroxyfengycin Aba Thr Met H 1112.7 C₇₂H₁₁₀N₁₁₂O₁₉S 1479.8 C15 Not observed MC Dehydroxyfengycin Val Thr Hcy H 1112.7 C₇₂H₁₁₀N₁₁₂O₁₉S 1479.8 C14, C15, C16 Not observed H Dehydroxyfengycin Ile Thr Ile H 1122.8 C₇₅H₁₁₆N₁₂O₁₉ 1489.9 C14, C15, C16 C14, C15, C16 I

REFERENCES

All publications, patent applications, patents, and other references cited herein are incorporated herein by reference in their entireties.

Although the foregoing subject matter has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be understood by those skilled in the art that certain changes and modifications can be practiced within the scope of the claims. 

That which is claimed:
 1. A composition for benefiting plant growth and/or plant health, the composition comprising: a biologically pure culture of Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof; and a biologically pure culture of Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof, wherein application of the composition to seed of the plant, roots of the plant, or soil surrounding the plant benefits plant growth and/or plant health.
 2. The composition of claim 1, wherein the composition is in the form of a liquid, an oil dispersion, a dust, a dry wettable powder, a spreadable granule, or a dry wettable granule.
 3. The composition of claim 1, wherein the composition is in the form of a liquid and each of the Bacillus subtilis RTI477 and the Bacillus amyloliquefaciens RTI301 are present at a concentration of from about 1.0×10⁸ CFU/ml to about 1.0×10¹² CFU/ml.
 4. The composition of claim 1, wherein the composition is in the form of a dust, a dry wettable powder, a spreadable granule, or a dry wettable granule and each of the Bacillus subtilis RTI477 and the Bacillus amyloliquefaciens RTI301 are present in an amount of from about 1.0×10⁸ CFU/g to about 1.0×10¹² CFU/g.
 5. The composition of claim 1, wherein the composition is in the form of an oil dispersion and each of the Bacillus subtilis RTI477 and the Bacillus amyloliquefaciens RTI301 are present at a concentration of from about 1.0×10⁸ CFU/ml to about 1.0×10¹² CFU/ml.
 6. The composition of claim 1, wherein each of the Bacillus subtilis RTI477 and the Bacillus amyloliquefaciens RTI301 are present in the form of spores or vegetative cells.
 7. The composition of claim 1, further comprising one or a combination of a carrier, a dispersant or a yeast extract.
 8. A plant seed coated with a composition for benefiting plant growth and/or plant health, the composition comprising: spores of a biologically pure culture of Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof; and spores of a biologically pure culture of Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof.
 9. The plant seed of claim 8, wherein each of the Bacillus subtilis RTI477 and the Bacillus amyloliquefaciens RTI301 are present in an amount ranging from about 1.0×10² CFU/seed to about 1.0×10⁹ CFU/seed.
 10. The plant seed of claim 8, further comprising one or a combination of a microbial, a biological, or a chemical insecticide, fungicide, nematicide, bacteriocide, herbicide, plant extract, plant growth regulator, or fertilizer present in an amount suitable to benefit plant growth and/or to confer protection against a pathogenic infection in the plant.
 11. The plant seed of claim 10, wherein the fungicide is one or more of benzovindiflupyr, anitiperonosporic, ametoctradin, amisulbrom, copper salts including copper hydroxide, copper oxychloride, copper sulfate, and copper persulfate, boscalid, thiflumazide, flutianil, furalaxyl, thiabendazole, benodanil, mepronil, isofetamid, fenfuram, bixafen, fluxapyroxad, penflufen, sedaxane, coumoxystrobin, enoxastrobin, flufenoxystrobin, pyraoxystrobin, pyrametostrobin, triclopyricarb, fenaminstrobin, metominostrobin, pyribencarb, meptyldinocap, fentin acetate, fentin chloride, fentin hydroxide, oxytetracycline, chlozolinate, chloroneb, tecnazene, etridiazole, iodocarb, prothiocarb, Bacillus subtilis syn., Bacillus amyloliquefaciens including strains QST 713, FZB24, MB1600, and D747, extract from Melaleuca alternifolia, extract from Lupinus albus doce, BLAD polypeptide, pyrisoxazole, oxpoconazole, etaconazole, fenpyrazamine, naftifine, terbinafine, validamycin, pyrimorph, valifenalate, fthalide, probenazole, isotianil, laminarin, extract from Reynoutria sachalinensis, phosphorous acid and salts, teclofthalam, triazoxide, pyriofenone, organic oils, potassium bicarbonate, chlorothalonil, fluoroimide; azoles, including bitertanol, bromuconazole, cyproconazole, difenoconazole, diniconazole, enilconazole, epoxiconazole, fluquinconazole, fenbuconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, metconazole, myclobutanil, penconazole, propiconazole, prothioconazole, simeconazole, triadimefon, triadimenol, tebuconazole, tetraconazole, triticonazole, prochloraz, pefurazoate, imazalil, triflumizole, cyazofamid, benomyl, carbendazim, thia-bendazole, fuberidazole, ethaboxam, etridiazole and hymexazole, azaconazole, diniconazole-M, oxpoconazol, paclobutrazol, uniconazol, 1-(4-chloro-phenyl)-2-([1,2,4]triazol-1-yl)-cycloheptanol and imazalilsulfphate; strobilurins, including azoxystrobin, dimoxystrobin, enestroburin, fluoxastrobin, kresoxim-methyl, methominostrobin, orysastrobin, picoxystrobin, pyraclostrobin, trifloxystrobin, enestroburin, methyl (2-chloro-5-[1-(3-methylbenzyloxyimino)ethyl]benzyl)carbamate, methyl (2-chloro-5-[1-(6-methylpyridin-2-ylmethoxyimino)ethyl]benzyl)carbamate and methyl 2-(ortho-(2,5-dimethylphenyloxymethylene)-phenyl)-3-methoxyacrylate, 2-(2-(6-(3-chloro-2-methyl-phenoxy)-5-fluoro-pyrimidin-4-yloxy)-phenyl)-2-methoxyimino-N-methyl-acetamide and 3-methoxy-2-(2-(N-(4-methoxy-phenyl)-cyclopropanecarboximidoylsulfanylmethyl)-phenyl)-acrylic acid methyl ester; carboxamides, including carboxin, benalaxyl, benalaxyl-M, fenhexamid, flutolanil, furametpyr, mepronil, metalaxyl, mefenoxam, ofurace, oxadixyl, oxycarboxin, penthiopyrad, isopyrazam, thifluzamide, tiadinil, 3,4-dichloro-N-(2-cyanophenyl)isothiazole-5-carboxamide, dimethomorph, flumorph, flumetover, fluopicolide (picobenzamid), zoxamide, carpropamid, diclocymet, mandipropamid, N-(2-(4-[3-(4-chlorophenyl)prop-2-ynyloxy]-3-methoxyphenyl)ethyl)-2-methanesulfonyl-amino-3-methylbutyramide, N-(2-(4-[3-(4-chloro-phenyl)prop-2-ynyloxy]-3-methoxy-phenyl)ethyl)-2-ethanesulfonylamino-3-methylbutyramide, methyl 3-(4-chlorophenyl)-3-(2-isopropoxycarbonyl-amino-3-methyl-butyrylamino)propionate, N-(4′-bromobiphenyl-2-yl)-4-difluoromethyl̂-methylthiazole-δ-carboxamide, N-(4′-trifluoromethyl-biphenyl-2-yl)-4-difluoromethyl-2-methylthiazole-5-carboxamide, N-(4′-chloro-3′-fluorobiphenyl-2-yl)-4-difluoromethyl-2-methyl-thiazole-5-carboxamide, N-(3\4′-dichloro-4-fluorobiphenyl-2-yl)-3-difluoro-methyl-1-methyl-pyrazole-4-carboxamide, N-(3′,4′-dichloro-5-fluorobiphenyl-2-yl)-3-difluoromethyl-1-methylpyrazole-4-carboxamide, N-(2-cyano-phenyl)-3,4-dichloroisothiazole-5-carboxamide, 2-amino-4-methyl-thiazole-5-carboxanilide, 2-chloro-N-(1,1,3-trimethyl-indan-4-yl)-nicotinamide, N-(2-(1,3-dimethylbutyl)-phenyl)-1,3-dimethyl-5-fluoro-1 H-pyrazole-4-carboxamide, N-(4′-chloro-3′,5-difluoro-biphenyl-2-yl)-3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxamide, N-(4′-chloro-3′,5-difluoro-biphenyl-2-yl)-3-trifluoromethyl-1-methyl-1H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-5-fluoro-biphenyl-2-yl)-3-trifluoromethyl-1-methyl-1H-pyrazole-4-carboxamide, N-(3′,5-difluoro-4′-methyl-biphenyl-2-yl)-3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxamide, N-(3′,5-difluoro-4′-methyl-biphenyl-2-yl)-3-trifluoromethyl-1-methyl-1H-pyrazole-4-carboxamide, N-(cis-2-bicyclopropyl-2-yl-phenyl)-3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxamide, N-(trans-2-bicyclopropyl-2-yl-phenyl)-3-difluoro-methyl-1-methyl-1 H-pyrazole-4-carboxamide, fluopyram, N-(3-ethyl-3,5-5-trimethyl-cyclohexyl)-3-formylamino-2-hydroxy-benzamide, oxytetracyclin, silthiofam, N-(6-methoxy-pyridin-3-yl) cyclopropanecarboxamide, 2-iodo-N-phenyl-benzamide, N-(2-bicyclo-propyl-2-yl-phenyl)-3-difluormethyl-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-1,3-dimethylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-1,3-dimethyl-5-fluoropyrazol-4-yl-carboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-5-chloro-1,3-dimethylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-3-fluoromethyl-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-3-(chlorofluoromethyl)-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-3-difluoromethyl-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-3-difluoromethyl-5-fluoro-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-5-chloro-3-difluoromethyl-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-3-(chlorodifluoromethyl)-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-1-methyl-3-trifluoromethylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-5-fluoro-1-methyl-3-trifluoromethylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-5-chloro-1-methyl-3-trifluoromethylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-1,3-dimethylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-1,3-dimethyl-5-fluoropyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-5-chloro-1,3-dimethylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-3-fluoromethyl-1-methylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-3-(chlorofluoromethyl)-1-methylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-3-difluoromethyl-1-methylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-3-difluoromethyl-5-fluoro-1-methylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-5-chloro-3-difluoromethyl-1-methylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-3-(chlorodifluoromethyl)-1-methylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-1-methyl-3-trifluoromethylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-5-fluoro-1-methyl-3-trifluoromethylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-5-chloro-1-methyl-3-trifluoromethylpyrazol-4-ylcarboxamide, N-(3′,4′-dichloro-3-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-3-fluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-difluoro-3-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxamide, N-(3′,4′-difluoro-3-fluorobiphenyl-2-yl)-1-methyl-S-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′-chloro-4′-fluoro-3-fluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-4-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-difluoro-4-fluorobiphenyl-2-yl)-1-methyl-S-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-4-fluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-difluoro-4-fluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′-chloro-4′-fluoro-4-fluorobiphenyl-2-yl)-1-methyl-S-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-5-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-difluoro-5-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-5-fluorobiphenyl-2-yl)-1-methyl-S-difluoromethyl-1 H-pyrazole-carboxamide, N-(3′,4′-difluoro-5-fluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-5-fluorobiphenyl-2-yl)-1,3-dimethyl-1 H-pyrazole-4-carboxamide, N-(3′-chloro-4′-fluoro-5-fluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(4′-fluoro-4-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(4′-fluoro-5-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxamide, N-(4′-chloro-5-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(4′-methyl-5-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(4′-fluoro-5-fluorobiphenyl-2-yl)-1,3-dimethyl-1 H-pyrazole-4-carboxamide, N-(4′-chloro-5-fluorobiphenyl-2-yl)-1,3-dimethyl-1 H-pyrazole-4-carboxamide, N-(4′-methyl-5-fluorobiphenyl-2-yl)-1,3-dimethyl-1 H-pyrazole-4-carboxamide, N-(4′-fluoro-6-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(4′-chloro-6-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-[2-(1,1,2,3,3,3-hexafluoropropoxy)-phenyl]-3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxamide, N-[4′-(trifluoromethylthio)-biphenyl-2-yl]-3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxamide and N-[4′-(trifluoromethylthio)-biphenyl-2-yl]-1-methyl-3-trifluoromethyl-1-methyl-1H-pyrazole-4-carboxamide; heterocyclic compounds, including fluazinam, pyrifenox, bupirimate, cyprodinil, fenarimol, ferimzone, mepanipyrim, nuarimol, pyrimethanil, triforine, fenpiclonil, fludioxonil, aldimorph, dodemorph, fenpropimorph, tridemorph, fenpropidin, iprodione, procymidone, vinclozolin, famoxadone, fenamidone, octhilinone, proben-azole, 5-chloro-7-(4-methyl-piperidin-1-yl)-6-(2,4,6-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidine, anilazine, diclomezine, pyroquilon, proquinazid, tricyclazole, 2-butoxy-6-iodo-3-propylchromen-4-one, acibenzolar-S-methyl, captafol, captan, dazomet, folpet, fenoxanil, quinoxyfen, N,N-dimethyl-3-(3-bromo-6-fluoro-2-methylindole-1-sulfonyl)-[1,2,4]triazole-1-sulfonamide, 5-ethyl-6-octyl-[1,2,4]triazolo[1,5-a]pyrimidin-2,7-diamine, 2,3,5,6-tetrachloro-4-methanesulfonyl-pyridine, 3,4,5-trichloro-pyridine-2,6-di-carbonitrile, N-(1-(5-bromo-3-chloro-pyridin-2-yl)-ethyl)-2,4-dichloro-nicotinamide, N-((5-bromo-3-chloro pyridin-2-yl)-methyl)-2,4-dichloro-nicotinamide, diflumetorim, nitrapyrin, dodemorphacetate, fluoroimid, blasticidin-S, chinomethionat, debacarb, difenzoquat, difenzoquat-methylsulphat, oxolinic acid and piperalin; carbamates, including mancozeb, maneb, metam, methasulphocarb, metiram, ferbam, propineb, thiram, zineb, ziram, diethofencarb, iprovalicarb, benthiavalicarb, propamocarb, propamocarb hydrochlorid, 4-fluorophenyl N-(1-(1-(4-cyanophenyl)-ethanesulfonyl)but-2-yl)carbamate, methyl 3-(4-chloro-phenyl)-3-(2-isopropoxycarbonylamino-3-methyl-butyrylamino)propanoate; and other fungicides, including guanidine, dodine, dodine free base, iminoctadine, guazatine, antibiotics: kasugamycin, oxytetracyclin and its salts, streptomycin, polyoxin, validamycin A, nitrophenyl derivatives: binapacryl, dinocap, dinobuton, sulfur-containing heterocyclyl compounds: dithianon, isoprothiolane, organometallic compounds: fentin salts, organophosphorus compounds: edifenphos, iprobenfos, fosetyl, fosetyl-aluminum, phosphorous acid and its salts, pyrazophos, tolclofos-methyl, organochlorine compounds: dichlofluanid, flusulfamide, hexachloro-benzene, phthalide, pencycuron, quintozene, thiophanate, thiophanate-methyl, tolylfluanid, others: cyflufenamid, cymoxanil, dimethirimol, ethirimol, furalaxyl, metrafenone and spiroxamine, guazatine-acetate, iminoc-tadine-triacetate, iminoctadine-tris(albesilate), kasugamycin hydrochloride hydrate, dichlorophen, pentachlorophenol and its salts, N-(4-chloro-2-nitro-phenyl)-N-ethyl-4-methyl-benzenesulfonamide, dicloran, nitrothal-isopropyl, tecnazen, biphenyl, bronopol, diphenylamine, mildiomycin, oxincopper, prohexadione calcium, N-(cyclopropylmethoxyimino-(6-difluoromethoxy-2,3-difluoro-phenyl)-methyl)-2-phenyl acetamide, N′-(4-(4-chloro-3-trifluoromethyl-phenoxy)-2,5-dimethyl-phenyl)-N-ethyl-N-methyl formamidine, N′-(4-(4-fluoro-3-trifluoromethyl-phenoxy)-2,5-dimethyl-phenyl)-N-ethyl-N-methyl formamidine, N′-(2-methyl-5-trifluormethyl-4-(3-trimethylsilanyl-propoxy)-phenyl)-N-ethyl-N-methylformamidine and N′-(5-difluormethyl-2-methyl-4-(3-trimethylsilanyl-propoxy)-phenyl)-N-ethyl-N-methyl formamidine.
 12. The plant seed of claim 10, wherein the fungicide is one or a combination of fluopyram, tebuconazole, chlorothalonil, thiophanate-methyl, prothioconazole, fludioxonil, metalaxyl, sedaxane, pyrazole carboxamides, or copper hydroxide.
 13. The plant seed of claim 10, wherein the insecticide is one or a combination of thiamethoxam, pyrethroids, bifenthrin, tefluthrin, zeta-cypermethrin, organophosphates, chlorethoxyphos, chlorpyrifos, tebupirimphos, cyfluthrin, fiproles, fipronil, nicotinoids, or clothianidin.
 14. A product comprising: a first composition comprising a biologically pure culture of Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof and a biologically pure culture of Bacillus amyloliquefaciens RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof; a second composition comprising one or a combination of a microbial, a biological, or a chemical insecticide, fungicide, nematicide, bacteriocide, herbicide, plant extract, plant growth regulator, or fertilizer, wherein the first and second composition are separately packaged; and instructions for delivering in an amount suitable to benefit plant growth, a combination of the first and second compositions to: foliage of the plant, bark of the plant, fruit of the plant, flowers of the plant, seed of the plant, roots of the plant, a cutting of the plant, a graft of the plant, callus tissue of the plant; soil or growth medium surrounding the plant; soil or growth medium before sowing seed of the plant in the soil or growth medium; or soil or growth medium before planting the plant, the plant cutting, the plant graft, or the plant callus tissue in the soil or growth medium.
 15. The product of claim 14, wherein the fungicide is one or more of benzovindiflupyr, anitiperonosporic, ametoctradin, amisulbrom, copper salts including copper hydroxide, copper oxychloride, copper sulfate, and copper persulfate, boscalid, thiflumazide, flutianil, furalaxyl, thiabendazole, benodanil, mepronil, isofetamid, fenfuram, bixafen, fluxapyroxad, penflufen, sedaxane, coumoxystrobin, enoxastrobin, flufenoxystrobin, pyraoxystrobin, pyrametostrobin, triclopyricarb, fenaminstrobin, metominostrobin, pyribencarb, meptyldinocap, fentin acetate, fentin chloride, fentin hydroxide, oxytetracycline, chlozolinate, chloroneb, tecnazene, etridiazole, iodocarb, prothiocarb, Bacillus subtilis syn., Bacillus amyloliquefaciens including strains QST 713, FZB24, MBI600, and D747, extract from Melaleuca alternifolia, extract from Lupinus albus doce, BLAD polypeptide, pyrisoxazole, oxpoconazole, etaconazole, fenpyrazamine, naftifine, terbinafine, validamycin, pyrimorph, valifenalate, fthalide, probenazole, isotianil, laminarin, extract from Reynoutria sachalinensis, phosphorous acid and salts, teclofthalam, triazoxide, pyriofenone, organic oils, potassium bicarbonate, chlorothalonil, fluoroimide; azoles, including bitertanol, bromuconazole, cyproconazole, difenoconazole, diniconazole, enilconazole, epoxiconazole, fluquinconazole, fenbuconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, metconazole, myclobutanil, penconazole, propiconazole, prothioconazole, simeconazole, triadimefon, triadimenol, tebuconazole, tetraconazole, triticonazole, prochloraz, pefurazoate, imazalil, triflumizole, cyazofamid, benomyl, carbendazim, thia-bendazole, fuberidazole, ethaboxam, etridiazole and hymexazole, azaconazole, diniconazole-M, oxpoconazol, paclobutrazol, uniconazol, 1-(4-chloro-phenyl)-2-([1,2,4]triazol-1-yl)-cycloheptanol and imazalilsulfphate; strobilurins, including azoxystrobin, dimoxystrobin, enestroburin, fluoxastrobin, kresoxim-methyl, methominostrobin, orysastrobin, picoxystrobin, pyraclostrobin, trifloxystrobin, enestroburin, methyl (2-chloro-5-[1-(3-methylbenzyloxyimino)ethyl]benzyl)carbamate, methyl (2-chloro-5-[1-(6-methylpyridin-2-ylmethoxyimino)ethyl]benzyl)carbamate and methyl 2-(ortho-(2,5-dimethylphenyloxymethylene)-phenyl)-3-methoxyacrylate, 2-(2-(6-(3-chloro-2-methyl-phenoxy)-5-fluoro-pyrimidin-4-yloxy)-phenyl)-2-methoxyimino-N-methyl-acetamide and 3-methoxy-2-(2-(N-(4-methoxy-phenyl)-cyclopropanecarboximidoylsulfanylmethyl)-phenyl)-acrylic acid methyl ester; carboxamides, including carboxin, benalaxyl, benalaxyl-M, fenhexamid, flutolanil, furametpyr, mepronil, metalaxyl, mefenoxam, ofurace, oxadixyl, oxycarboxin, penthiopyrad, isopyrazam, thifluzamide, tiadinil, 3,4-dichloro-N-(2-cyanophenyl)isothiazole-5-carboxamide, dimethomorph, flumorph, flumetover, fluopicolide (picobenzamid), zoxamide, carpropamid, diclocymet, mandipropamid, N-(2-(4-[3-(4-chlorophenyl)prop-2-ynyloxy]-3-methoxyphenyl)ethyl)-2-methanesulfonyl-amino-3-methylbutyramide, N-(2-(4-[3-(4-chloro-phenyl)prop-2-ynyloxy]-3-methoxy-phenyl)ethyl)-2-ethanesulfonylamino-3-methylbutyramide, methyl 3-(4-chlorophenyl)-3-(2-isopropoxycarbonyl-amino-3-methyl-butyrylamino)propionate, N-(4′-bromobiphenyl-2-yl)-4-difluoromethyl̂-methylthiazole-δ-carboxamide, N-(4′-trifluoromethyl-biphenyl-2-yl)-4-difluoromethyl-2-methylthiazole-5-carboxamide, N-(4′-chloro-3′-fluorobiphenyl-2-yl)-4-difluoromethyl-2-methyl-thiazole-5-carboxamide, N-(3\4′-dichloro-4-fluorobiphenyl-2-yl)-3-difluoro-methyl-1-methyl-pyrazole-4-carboxamide, N-(3′,4′-dichloro-5-fluorobiphenyl-2-yl)-3-difluoromethyl-1-methylpyrazole-4-carboxamide, N-(2-cyano-phenyl)-3,4-dichloroisothiazole-5-carboxamide, 2-amino-4-methyl-thiazole-5-carboxanilide, 2-chloro-N-(1,1,3-trimethyl-indan-4-yl)-nicotinamide, N-(2-(1,3-dimethylbutyl)-phenyl)-1,3-dimethyl-5-fluoro-1 H-pyrazole-4-carboxamide, N-(4′-chloro-3′,5-difluoro-biphenyl-2-yl)-3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxamide, N-(4′-chloro-3′,5-difluoro-biphenyl-2-yl)-3-trifluoromethyl-1-methyl-1H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-5-fluoro-biphenyl-2-yl)-3-trifluoromethyl-1-methyl-1H-pyrazole-4-carboxamide, N-(3′,5-difluoro-4′-methyl-biphenyl-2-yl)-3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxamide, N-(3′,5-difluoro-4′-methyl-biphenyl-2-yl)-3-trifluoromethyl-1-methyl-1H-pyrazole-4-carboxamide, N-(cis-2-bicyclopropyl-2-yl-phenyl)-3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxamide, N-(trans-2-bicyclopropyl-2-yl-phenyl)-3-difluoro-methyl-1-methyl-1 H-pyrazole-4-carboxamide, fluopyram, N-(3-ethyl-3,5-5-trimethyl-cyclohexyl)-3-formylamino-2-hydroxy-benzamide, oxytetracyclin, silthiofam, N-(6-methoxy-pyridin-3-yl) cyclopropanecarboxamide, 2-iodo-N-phenyl-benzamide, N-(2-bicyclo-propyl-2-yl-phenyl)-3-difluormethyl-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-1,3-dimethylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-1,3-dimethyl-5-fluoropyrazol-4-yl-carboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-5-chloro-1,3-dimethylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-3-fluoromethyl-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-3-(chlorofluoromethyl)-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-3-difluoromethyl-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-3-difluoromethyl-5-fluoro-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-5-chloro-3-difluoromethyl-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-3-(chlorodifluoromethyl)-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-1-methyl-3-trifluoromethylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-5-fluoro-1-methyl-3-trifluoromethylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-5-chloro-1-methyl-3-trifluoromethylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-1,3-dimethylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-1,3-dimethyl-5-fluoropyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-5-chloro-1,3-dimethylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-3-fluoromethyl-1-methylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-3-(chlorofluoromethyl)-1-methylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-3-difluoromethyl-1-methylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-3-difluoromethyl-5-fluoro-1-methylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-5-chloro-3-difluoromethyl-1-methylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-3-(chlorodifluoromethyl)-1-methylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-1-methyl-3-trifluoromethylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-5-fluoro-1-methyl-3-trifluoromethylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-5-chloro-1-methyl-3-trifluoromethylpyrazol-4-ylcarboxamide, N-(3′,4′-dichloro-3-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-3-fluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-difluoro-3-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxamide, N-(3′,4′-difluoro-3-fluorobiphenyl-2-yl)-1-methyl-S-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′-chloro-4′-fluoro-3-fluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-4-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-difluoro-4-fluorobiphenyl-2-yl)-1-methyl-S-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-4-fluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-difluoro-4-fluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′-chloro-4′-fluoro-4-fluorobiphenyl-2-yl)-1-methyl-S-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-5-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-difluoro-5-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-5-fluorobiphenyl-2-yl)-1-methyl-S-difluoromethyl-1 H-pyrazole-carboxamide, N-(3′,4′-difluoro-5-fluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-5-fluorobiphenyl-2-yl)-1,3-dimethyl-1 H-pyrazole-4-carboxamide, N-(3′-chloro-4′-fluoro-5-fluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(4′-fluoro-4-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(4′-fluoro-5-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxamide, N-(4′-chloro-5-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(4′-methyl-5-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(4′-fluoro-5-fluorobiphenyl-2-yl)-1,3-dimethyl-1 H-pyrazole-4-carboxamide, N-(4′-chloro-5-fluorobiphenyl-2-yl)-1,3-dimethyl-1 H-pyrazole-4-carboxamide, N-(4′-methyl-5-fluorobiphenyl-2-yl)-1,3-dimethyl-1 H-pyrazole-4-carboxamide, N-(4′-fluoro-6-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(4′-chloro-6-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-[2-(1,1,2,3,3,3-hexafluoropropoxy)-phenyl]-3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxamide, N-[4′-(trifluoromethylthio)-biphenyl-2-yl]-3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxamide and N-[4′-(trifluoromethylthio)-biphenyl-2-yl]-1-methyl-3-trifluoromethyl-1-methyl-1H-pyrazole-4-carboxamide; heterocyclic compounds, including fluazinam, pyrifenox, bupirimate, cyprodinil, fenarimol, ferimzone, mepanipyrim, nuarimol, pyrimethanil, triforine, fenpiclonil, fludioxonil, aldimorph, dodemorph, fenpropimorph, tridemorph, fenpropidin, iprodione, procymidone, vinclozolin, famoxadone, fenamidone, octhilinone, proben-azole, 5-chloro-7-(4-methyl-piperidin-1-yl)-6-(2,4,6-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidine, anilazine, diclomezine, pyroquilon, proquinazid, tricyclazole, 2-butoxy-6-iodo-3-propylchromen-4-one, acibenzolar-S-methyl, captafol, captan, dazomet, folpet, fenoxanil, quinoxyfen, N,N-dimethyl-3-(3-bromo-6-fluoro-2-methylindole-1-sulfonyl)-[1,2,4]triazole-1-sulfonamide, 5-ethyl-6-octyl-[1,2,4]triazolo[1,5-a]pyrimidin-2,7-diamine, 2,3,5,6-tetrachloro-4-methanesulfonyl-pyridine, 3,4,5-trichloro-pyridine-2,6-di-carbonitrile, N-(1-(5-bromo-3-chloro-pyridin-2-yl)-ethyl)-2,4-dichloro-nicotinamide, N-((5-bromo-3-chloro pyridin-2-yl)-methyl)-2,4-dichloro-nicotinamide, diflumetorim, nitrapyrin, dodemorphacetate, fluoroimid, blasticidin-S, chinomethionat, debacarb, difenzoquat, difenzoquat-methylsulphat, oxolinic acid and piperalin; carbamates, including mancozeb, maneb, metam, methasulphocarb, metiram, ferbam, propineb, thiram, zineb, ziram, diethofencarb, iprovalicarb, benthiavalicarb, propamocarb, propamocarb hydrochlorid, 4-fluorophenyl N-(1-(1-(4-cyanophenyl)-ethanesulfonyl)but-2-yl)carbamate, methyl 3-(4-chloro-phenyl)-3-(2-isopropoxycarbonylamino-3-methyl-butyrylamino)propanoate; and other fungicides, including guanidine, dodine, dodine free base, iminoctadine, guazatine, antibiotics: kasugamycin, oxytetracyclin and its salts, streptomycin, polyoxin, validamycin A, nitrophenyl derivatives: binapacryl, dinocap, dinobuton, sulfur-containing heterocyclyl compounds: dithianon, isoprothiolane, organometallic compounds: fentin salts, organophosphorus compounds: edifenphos, iprobenfos, fosetyl, fosetyl-aluminum, phosphorous acid and its salts, pyrazophos, tolclofos-methyl, organochlorine compounds: dichlofluanid, flusulfamide, hexachloro-benzene, phthalide, pencycuron, quintozene, thiophanate, thiophanate-methyl, tolylfluanid, others: cyflufenamid, cymoxanil, dimethirimol, ethirimol, furalaxyl, metrafenone and spiroxamine, guazatine-acetate, iminoc-tadine-triacetate, iminoctadine-tris(albesilate), kasugamycin hydrochloride hydrate, dichlorophen, pentachlorophenol and its salts, N-(4-chloro-2-nitro-phenyl)-N-ethyl-4-methyl-benzenesulfonamide, dicloran, nitrothal-isopropyl, tecnazen, biphenyl, bronopol, diphenylamine, mildiomycin, oxincopper, prohexadione calcium, N-(cyclopropylmethoxyimino-(6-difluoromethoxy-2,3-difluoro-phenyl)-methyl)-2-phenyl acetamide, N′-(4-(4-chloro-3-trifluoromethyl-phenoxy)-2,5-dimethyl-phenyl)-N-ethyl-N-methyl formamidine, N′-(4-(4-fluoro-3-trifluoromethyl-phenoxy)-2,5-dimethyl-phenyl)-N-ethyl-N-methyl formamidine, N′-(2-methyl-5-trifluormethyl-4-(3-trimethylsilanyl-propoxy)-phenyl)-N-ethyl-N-methylformamidine and N′-(5-difluormethyl-2-methyl-4-(3-trimethylsilanyl-propoxy)-phenyl)-N-ethyl-N-methyl formamidine.
 16. The product of claim 14, wherein the fungicide is selected from the group consisting of fluopyram, tebuconazole, chlorothalonil, thiophanate-methyl, prothioconazole, fludioxonil, metalaxyl, sedaxane, pyrazole carboxamides, and copper hydroxide.
 17. The product of claim 14, wherein the insecticide is one or a combination of thiamethoxam, pyrethroids, bifenthrin, tefluthrin, zeta-cypermethrin, organophosphates, chlorethoxyphos, chlorpyrifos, tebupirimphos, cyfluthrin, fiproles, fipronil, nicotinoids, or clothianidin.
 18. The product of claim 14, wherein the insecticide comprises bifenthrin.
 19. The product of claim 18, wherein the second composition is in a formulation compatible with a liquid fertilizer.
 20. The product of claim 14, wherein the first composition further comprises one or a combination of a carrier, a dispersant, or a yeast extract.
 21. The product of claim 14, wherein the first composition is in the form of a liquid and each of the Bacillus amyloliquefaciens RTI301 and the Bacillus subtilis RTI477 is present at a concentration of from about 1.0×10⁸ CFU/ml to about 1.0×10¹² CFU/ml.
 22. The product of claim 14, wherein the first composition is in the form of a dust, a dry wettable powder, a spreadable granule, or a dry wettable granule and each of the Bacillus amyloliquefaciens RTI301 and the Bacillus subtilis RTI477 is present in an amount of from about 1.0×10⁸ CFU/g to about 1.0×10¹² CFU/g.
 23. A composition for benefiting plant growth and/or plant health, the composition comprising: a biologically pure culture of Bacillus amyloliquefaciens RTI301 deposited as ATCC No. PTA-121165, or a mutant thereof having all the identifying characteristics thereof; a biologically pure culture of Bacillus subtilis RTI477 deposited as ATCC No. PTA-121167, or a mutant thereof having all the identifying characteristics thereof; and one or a combination of a microbial, a biological, or a chemical insecticide, fungicide, nematicide, bacteriocide, herbicide, plant extract, plant growth regulator, or fertilizer present in an amount suitable to benefit plant growth and/or to confer protection against a pathogenic infection in the plant, wherein application of the composition to seed of the plant, roots of the plant, or soil surrounding the plant benefits plant growth and/or plant health.
 24. The composition of claim 23, wherein the composition is in the form of a liquid and each of the Bacillus subtilis RTI477 and the Bacillus amyloliquefaciens RTI301 are present at a concentration of from about 1.0×10⁸ CFU/ml to about 1.0×10¹² CFU/ml.
 25. The composition of claim 23, wherein the composition is in the form of a dust, a dry wettable powder, a spreadable granule, or a dry wettable granule and each of the Bacillus subtilis RTI477 and the Bacillus amyloliquefaciens RTI301 are present in an amount of from about 1.0×10⁸ CFU/g to about 1.0×10¹² CFU/g.
 26. The composition of claim 23, wherein each of the Bacillus subtilis RTI477 and the Bacillus amyloliquefaciens RTI301 are present in the form of spores or vegetative cells.
 27. The composition of claim 23, wherein the fungicide is one or more of benzovindiflupyr, anitiperonosporic, ametoctradin, amisulbrom, copper salts including copper hydroxide, copper oxychloride, copper sulfate, and copper persulfate, boscalid, thiflumazide, flutianil, furalaxyl, thiabendazole, benodanil, mepronil, isofetamid, fenfuram, bixafen, fluxapyroxad, penflufen, sedaxane, coumoxystrobin, enoxastrobin, flufenoxystrobin, pyraoxystrobin, pyrametostrobin, triclopyricarb, fenaminstrobin, metominostrobin, pyribencarb, meptyldinocap, fentin acetate, fentin chloride, fentin hydroxide, oxytetracycline, chlozolinate, chloroneb, tecnazene, etridiazole, iodocarb, prothiocarb, Bacillus subtilis syn., Bacillus amyloliquefaciens including strains QST 713, FZB24, MBI600, and D747, extract from Melaleuca alternifolia, extract from Lupinus albus doce, BLAD polypeptide, pyrisoxazole, oxpoconazole, etaconazole, fenpyrazamine, naftifine, terbinafine, validamycin, pyrimorph, valifenalate, fthalide, probenazole, isotianil, laminarin, extract from Reynoutria sachalinensis, phosphorous acid and salts, teclofthalam, triazoxide, pyriofenone, organic oils, potassium bicarbonate, chlorothalonil, fluoroimide; azoles, including bitertanol, bromuconazole, cyproconazole, difenoconazole, diniconazole, enilconazole, epoxiconazole, fluquinconazole, fenbuconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, metconazole, myclobutanil, penconazole, propiconazole, prothioconazole, simeconazole, triadimefon, triadimenol, tebuconazole, tetraconazole, triticonazole, prochloraz, pefurazoate, imazalil, triflumizole, cyazofamid, benomyl, carbendazim, thia-bendazole, fuberidazole, ethaboxam, etridiazole and hymexazole, azaconazole, diniconazole-M, oxpoconazol, paclobutrazol, uniconazol, 1-(4-chloro-phenyl)-2-([1,2,4]triazol-1-yl)-cycloheptanol and imazalilsulfphate; strobilurins, including azoxystrobin, dimoxystrobin, enestroburin, fluoxastrobin, kresoxim-methyl, methominostrobin, orysastrobin, picoxystrobin, pyraclostrobin, trifloxystrobin, enestroburin, methyl (2-chloro-5-[1-(3-methylbenzyloxyimino)ethyl]benzyl)carbamate, methyl (2-chloro-5-[1-(6-methylpyridin-2-ylmethoxyimino)ethyl]benzyl)carbamate and methyl 2-(ortho-(2,5-dimethylphenyloxymethylene)-phenyl)-3-methoxyacrylate, 2-(2-(6-(3-chloro-2-methyl-phenoxy)-5-fluoro-pyrimidin-4-yloxy)-phenyl)-2-methoxyimino-N-methyl-acetamide and 3-methoxy-2-(2-(N-(4-methoxy-phenyl)-cyclopropanecarboximidoylsulfanylmethyl)-phenyl)-acrylic acid methyl ester; carboxamides, including carboxin, benalaxyl, benalaxyl-M, fenhexamid, flutolanil, furametpyr, mepronil, metalaxyl, mefenoxam, ofurace, oxadixyl, oxycarboxin, penthiopyrad, isopyrazam, thifluzamide, tiadinil, 3,4-dichloro-N-(2-cyanophenyl)isothiazole-5-carboxamide, dimethomorph, flumorph, flumetover, fluopicolide (picobenzamid), zoxamide, carpropamid, diclocymet, mandipropamid, N-(2-(4-[3-(4-chlorophenyl)prop-2-ynyloxy]-3-methoxyphenyl)ethyl)-2-methanesulfonyl-amino-3-methylbutyramide, N-(2-(4-[3-(4-chloro-phenyl)prop-2-ynyloxy]-3-methoxy-phenyl)ethyl)-2-ethanesulfonylamino-3-methylbutyramide, methyl 3-(4-chlorophenyl)-3-(2-isopropoxycarbonyl-amino-3-methyl-butyrylamino)propionate, N-(4′-bromobiphenyl-2-yl)-4-difluoromethyl̂-methylthiazole-δ-carboxamide, N-(4′-trifluoromethyl-biphenyl-2-yl)-4-difluoromethyl-2-methylthiazole-5-carboxamide, N-(4′-chloro-3′-fluorobiphenyl-2-yl)-4-difluoromethyl-2-methyl-thiazole-5-carboxamide, N-(3\4′-dichloro-4-fluorobiphenyl-2-yl)-3-difluoro-methyl-1-methyl-pyrazole-4-carboxamide, N-(3′,4′-dichloro-5-fluorobiphenyl-2-yl)-3-difluoromethyl-1-methylpyrazole-4-carboxamide, N-(2-cyano-phenyl)-3,4-dichloroisothiazole-5-carboxamide, 2-amino-4-methyl-thiazole-5-carboxanilide, 2-chloro-N-(1,1,3-trimethyl-indan-4-yl)-nicotinamide, N-(2-(1,3-dimethylbutyl)-phenyl)-1,3-dimethyl-5-fluoro-1 H-pyrazole-4-carboxamide, N-(4′-chloro-3′,5-difluoro-biphenyl-2-yl)-3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxamide, N-(4′-chloro-3′,5-difluoro-biphenyl-2-yl)-3-trifluoromethyl-1-methyl-1H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-5-fluoro-biphenyl-2-yl)-3-trifluoromethyl-1-methyl-1H-pyrazole-4-carboxamide, N-(3′,5-difluoro-4′-methyl-biphenyl-2-yl)-3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxamide, N-(3′,5-difluoro-4′-methyl-biphenyl-2-yl)-3-trifluoromethyl-1-methyl-1H-pyrazole-4-carboxamide, N-(cis-2-bicyclopropyl-2-yl-phenyl)-3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxamide, N-(trans-2-bicyclopropyl-2-yl-phenyl)-3-difluoro-methyl-1-methyl-1 H-pyrazole-4-carboxamide, fluopyram, N-(3-ethyl-3,5-5-trimethyl-cyclohexyl)-3-formylamino-2-hydroxy-benzamide, oxytetracyclin, silthiofam, N-(6-methoxy-pyridin-3-yl) cyclopropanecarboxamide, 2-iodo-N-phenyl-benzamide, N-(2-bicyclo-propyl-2-yl-phenyl)-3-difluormethyl-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-1,3-dimethylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-1,3-dimethyl-5-fluoropyrazol-4-yl-carboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-5-chloro-1,3-dimethylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-3-fluoromethyl-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-3-(chlorofluoromethyl)-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-3-difluoromethyl-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-3-difluoromethyl-5-fluoro-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-5-chloro-3-difluoromethyl-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-3-(chlorodifluoromethyl)-1-methylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-1-methyl-3-trifluoromethylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-5-fluoro-1-methyl-3-trifluoromethylpyrazol-4-ylcarboxamide, N-(3′,4′,5′-trifluorobiphenyl-2-yl)-5-chloro-1-methyl-3-trifluoromethylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-1,3-dimethylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-1,3-dimethyl-5-fluoropyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-5-chloro-1,3-dimethylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-3-fluoromethyl-1-methylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-3-(chlorofluoromethyl)-1-methylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-3-difluoromethyl-1-methylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-3-difluoromethyl-5-fluoro-1-methylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-5-chloro-3-difluoromethyl-1-methylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-3-(chlorodifluoromethyl)-1-methylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-1-methyl-3-trifluoromethylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-5-fluoro-1-methyl-3-trifluoromethylpyrazol-4-ylcarboxamide, N-(2′,4′,5′-trifluorobiphenyl-2-yl)-5-chloro-1-methyl-3-trifluoromethylpyrazol-4-ylcarboxamide, N-(3′,4′-dichloro-3-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-3-fluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-difluoro-3-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxamide, N-(3′,4′-difluoro-3-fluorobiphenyl-2-yl)-1-methyl-S-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′-chloro-4′-fluoro-3-fluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-4-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-difluoro-4-fluorobiphenyl-2-yl)-1-methyl-S-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-4-fluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-difluoro-4-fluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′-chloro-4′-fluoro-4-fluorobiphenyl-2-yl)-1-methyl-S-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-5-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-difluoro-5-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-5-fluorobiphenyl-2-yl)-1-methyl-S-difluoromethyl-1 H-pyrazole-carboxamide, N-(3′,4′-difluoro-5-fluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(3′,4′-dichloro-5-fluorobiphenyl-2-yl)-1,3-dimethyl-1 H-pyrazole-4-carboxamide, N-(3′-chloro-4′-fluoro-5-fluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 H-pyrazole-4-carboxamide, N-(4′-fluoro-4-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(4′-fluoro-5-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxamide, N-(4′-chloro-5-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(4′-methyl-5-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(4′-fluoro-5-fluorobiphenyl-2-yl)-1,3-dimethyl-1 H-pyrazole-4-carboxamide, N-(4′-chloro-5-fluorobiphenyl-2-yl)-1,3-dimethyl-1 H-pyrazole-4-carboxamide, N-(4′-methyl-5-fluorobiphenyl-2-yl)-1,3-dimethyl-1 H-pyrazole-4-carboxamide, N-(4′-fluoro-6-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-(4′-chloro-6-fluorobiphenyl-2-yl)-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxamide, N-[2-(1,1,2,3,3,3-hexafluoropropoxy)-phenyl]-3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxamide, N-[4′-(trifluoromethylthio)-biphenyl-2-yl]-3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxamide and N-[4′-(trifluoromethylthio)-biphenyl-2-yl]-1-methyl-3-trifluoromethyl-1-methyl-1H-pyrazole-4-carboxamide; heterocyclic compounds, including fluazinam, pyrifenox, bupirimate, cyprodinil, fenarimol, ferimzone, mepanipyrim, nuarimol, pyrimethanil, triforine, fenpiclonil, fludioxonil, aldimorph, dodemorph, fenpropimorph, tridemorph, fenpropidin, iprodione, procymidone, vinclozolin, famoxadone, fenamidone, octhilinone, proben-azole, 5-chloro-7-(4-methyl-piperidin-1-yl)-6-(2,4,6-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidine, anilazine, diclomezine, pyroquilon, proquinazid, tricyclazole, 2-butoxy-6-iodo-3-propylchromen-4-one, acibenzolar-S-methyl, captafol, captan, dazomet, folpet, fenoxanil, quinoxyfen, N,N-dimethyl-3-(3-bromo-6-fluoro-2-methylindole-1-sulfonyl)-[1,2,4]triazole-1-sulfonamide, 5-ethyl-6-octyl-[1,2,4]triazolo[1,5-a]pyrimidin-2,7-diamine, 2,3,5,6-tetrachloro-4-methanesulfonyl-pyridine, 3,4,5-trichloro-pyridine-2,6-di-carbonitrile, N-(1-(5-bromo-3-chloro-pyridin-2-yl)-ethyl)-2,4-dichloro-nicotinamide, N-((5-bromo-3-chloro pyridin-2-yl)-methyl)-2,4-dichloro-nicotinamide, diflumetorim, nitrapyrin, dodemorphacetate, fluoroimid, blasticidin-S, chinomethionat, debacarb, difenzoquat, difenzoquat-methylsulphat, oxolinic acid and piperalin; carbamates, including mancozeb, maneb, metam, methasulphocarb, metiram, ferbam, propineb, thiram, zineb, ziram, diethofencarb, iprovalicarb, benthiavalicarb, propamocarb, propamocarb hydrochlorid, 4-fluorophenyl N-(1-(1-(4-cyanophenyl)-ethanesulfonyl)but-2-yl)carbamate, methyl 3-(4-chloro-phenyl)-3-(2-isopropoxycarbonylamino-3-methyl-butyrylamino)propanoate; and other fungicides, including guanidine, dodine, dodine free base, iminoctadine, guazatine, antibiotics: kasugamycin, oxytetracyclin and its salts, streptomycin, polyoxin, validamycin A, nitrophenyl derivatives: binapacryl, dinocap, dinobuton, sulfur-containing heterocyclyl compounds: dithianon, isoprothiolane, organometallic compounds: fentin salts, organophosphorus compounds: edifenphos, iprobenfos, fosetyl, fosetyl-aluminum, phosphorous acid and its salts, pyrazophos, tolclofos-methyl, organochlorine compounds: dichlofluanid, flusulfamide, hexachloro-benzene, phthalide, pencycuron, quintozene, thiophanate, thiophanate-methyl, tolylfluanid, others: cyflufenamid, cymoxanil, dimethirimol, ethirimol, furalaxyl, metrafenone and spiroxamine, guazatine-acetate, iminoc-tadine-triacetate, iminoctadine-tris(albesilate), kasugamycin hydrochloride hydrate, dichlorophen, pentachlorophenol and its salts, N-(4-chloro-2-nitro-phenyl)-N-ethyl-4-methyl-benzenesulfonamide, dicloran, nitrothal-isopropyl, tecnazen, biphenyl, bronopol, diphenylamine, mildiomycin, oxincopper, prohexadione calcium, N-(cyclopropylmethoxyimino-(6-difluoromethoxy-2,3-difluoro-phenyl)-methyl)-2-phenyl acetamide, N′-(4-(4-chloro-3-trifluoromethyl-phenoxy)-2,5-dimethyl-phenyl)-N-ethyl-N-methyl formamidine, N′-(4-(4-fluoro-3-trifluoromethyl-phenoxy)-2,5-dimethyl-phenyl)-N-ethyl-N-methyl formamidine, N′-(2-methyl-5-trifluormethyl-4-(3-trimethylsilanyl-propoxy)-phenyl)-N-ethyl-N-methylformamidine and N′-(5-difluormethyl-2-methyl-4-(3-trimethylsilanyl-propoxy)-phenyl)-N-ethyl-N-methyl formamidine.
 28. The composition of claim 23, wherein the fungicide is selected from the group consisting of fluopyram, tebuconazole, chlorothalonil, thiophanate-methyl, prothioconazole, fludioxonil, metalaxyl, sedaxane, pyrazole carboxamides, and copper hydroxide.
 29. The composition of claim 23, wherein the insecticide is one or a combination of thiamethoxam pyrethroids, bifenthrin, tefluthrin, zeta-cypermethrin, organophosphates, chlorethoxyphos, chlorpyrifos, tebupirimphos, cyfluthrin, fiproles, fipronil, nicotinoids, or clothianidin.
 30. The composition of claim 23, wherein the insecticide comprises bifenthrin and the composition is in a formulation compatible with a liquid fertilizer. 